A Research Guide for
Sleep Disorders

Insomnia means difficulty falling asleep, staying asleep, or waking too early and being unable to return to sleep — despite having adequate opportunity and a suitable environment — together with a daytime consequence such as fatigue, low mood, irritability, or impaired concentration. It is called chronic insomnia disorder when it occurs at least three nights a week for at least three months.

Chronic insomnia affects roughly 10 to 15 percent of adults, making it one of the most common health complaints. It is more common in women and tends to increase with age.

The 3P model explains how insomnia becomes chronic: predisposing factors set the baseline (a tendency toward worry, light sleeping temperament, family history); a precipitating factor triggers an episode (stress, illness, grief, pain); and perpetuating factors keep the insomnia going after the trigger has passed — well-intentioned coping behaviors like going to bed much earlier, lying awake for hours “trying,” napping, or extra caffeine. Over time the bed itself becomes associated with frustration and wakefulness.

Restless legs syndrome (RLS) is a neurological sensorimotor disorder: a strong, uncomfortable urge to move the legs, often with sensations described as crawling, pulling, aching, or “electric.” Five features define it, easily remembered with the word URGE — an Urge to move the legs, worsened by Rest, relieved by Getting up and moving, and with Evening or night predominance. The symptoms must not be fully explained by another condition such as leg cramps.

Clinically significant RLS affects roughly 2 to 3 percent of adults severely enough to warrant treatment. It runs strongly in families.

The biology: RLS involves the brain’s dopamine signaling and, importantly, iron — specifically iron availability within the brain, which can be low even when standard blood counts are normal. This is why iron studies are central to the evaluation.

Primary vs. secondary RLS: Primary RLS is often familial and lifelong. Secondary RLS is caused or worsened by something identifiable — iron deficiency, pregnancy, kidney failure, peripheral neuropathy, or certain medications. Distinguishing the two changes the treatment approach.

Excessive daytime sleepiness (EDS) is more than ordinary tiredness. It means difficulty staying awake and alert during the day, sometimes with unintended sleep episodes — dozing off in meetings, while reading, or dangerously while driving. EDS is a symptom, not a diagnosis. The clinical task is to find its cause.

The common causes, roughly in order of frequency:

• Insufficient sleep — the most common cause and the most overlooked, because the person has adapted to feeling tired.
• Obstructive sleep apnea — repeated fragmentation of sleep by breathing interruptions leaves sleep unrefreshing regardless of how many hours are spent in bed.
• Circadian misalignment — shift work or a delayed body clock.
• Medications and substances — sedating antihistamines, some antidepressants, opioids, certain blood pressure drugs, alcohol.
• Narcolepsy — a chronic neurological disorder of sleep-wake regulation. Type 1 involves the loss of a brain signaling chemical called orexin and is marked by cataplexy (sudden brief muscle weakness triggered by emotion). Type 2 lacks cataplexy. Both feature severe sleepiness.
• Idiopathic hypersomnia — excessive sleep need and profound difficulty waking, without the specific features of narcolepsy.
• Depression and other medical conditions — depression commonly presents with fatigue and excessive sleep; so can thyroid disease, anemia, and chronic illness.

Obstructive sleep apnea (OSA) is the repeated narrowing or collapse of the upper airway during sleep. Each event either stops airflow (an apnea) or sharply reduces it (a hypopnea), often causing a drop in blood oxygen and a brief brain arousal. These arousals fragment sleep, sometimes hundreds of times a night.

Severity is graded by the apnea-hypopnea index (AHI): 5 to 15 events per hour is mild, 15 to 30 is moderate, above 30 is severe.

Typical signs: loud habitual snoring; witnessed breathing pauses; gasping or choking during sleep; waking unrefreshed; morning headache or dry mouth; nighttime urination; daytime sleepiness. Risk rises with excess weight, larger neck circumference, male sex, and older age — but OSA also occurs in slim people and in women, where it is more often missed.

Why it matters: Beyond sleepiness and safety, untreated moderate-to-severe OSA is strongly associated with high blood pressure, atrial fibrillation, heart failure, stroke, type 2 diabetes, and motor vehicle crashes. It is highly treatable, which makes finding it worthwhile.

A related condition — upper airway resistance syndrome (UARS): Some people have repeated arousals from increasing respiratory effort without meeting the AHI threshold for a formal OSA diagnosis. This is called upper airway resistance syndrome. It causes the same daytime sleepiness and fatigue but can be missed on a standard home sleep test because the AHI appears normal. If you have significant symptoms but a low AHI, ask your sleep clinician about UARS — an in-laboratory polysomnography with respiratory effort measurement can detect it.

These are problems of timing rather than of sleep itself. The person can often sleep well — just not at the hours their schedule demands.

• Delayed sleep-wake phase disorder: the body clock is shifted late — natural sleep onset at 2 to 4 a.m. and natural wake time late morning. Common in adolescents and young adults. It is not laziness — it has a biological basis.
• Advanced sleep-wake phase disorder: the mirror image — asleep by early evening, awake at 3 to 4 a.m. More common with older age.
• Shift work disorder: insomnia, sleepiness, or both arising because work hours conflict with the body clock.
• Jet lag disorder: temporary misalignment after rapid travel across time zones.
• Non-24-hour and irregular types: less common; the non-24-hour type affects many totally blind people whose clock drifts because it cannot be reset by light.

• Insomnia and sleep apnea frequently coexist. This combination is common enough to have its own name — COMISA (comorbid insomnia and sleep apnea). Treating only the insomnia, especially with sleeping pills, while leaving apnea untreated is a setup for disappointment and can be unsafe. If you have both: Evidence supports starting CBT-I (cognitive behavioral therapy for insomnia) at the same time as PAP therapy, or even slightly before. Addressing the insomnia first actually improves how well you tolerate and use the PAP machine. Treating apnea alone often leaves the insomnia unresolved because the conditioned wakefulness has become self-sustaining.
• Treating one often improves the others. Effectively treating OSA commonly reduces coexisting insomnia and can improve restless legs symptoms.
• Restless legs masquerades as insomnia. People with RLS often report only “I can’t fall asleep” without mentioning leg sensations, because they have stopped noticing them or do not think they are relevant.
• Circadian disorders masquerade as insomnia or sleepiness. A delayed body clock looks exactly like insomnia at bedtime and sleepiness in the morning. The treatments are different.
• Depression and anxiety run through all of it. Mood disorders both cause and result from disrupted sleep. Good care addresses both rather than forcing a choice about which came first.
• Untreated apnea worsens nearly everything. It fragments sleep, aggravates restless legs, undermines insomnia treatment, and worsens mood and metabolic health. This is the central reason the guide urges screening for OSA early.

When evaluating any sleep product or claim, ask these questions:

• Is it supported by a clinical guideline or randomized trials — or only by testimonials and marketing?
• Does it claim to fix many unrelated problems at once? Broad claims are a warning sign.
• Is it being offered instead of an accurate diagnosis? Nothing should displace identifying the actual cause.
• What is the harm if it does not work — lost money, lost time, or a missed real diagnosis?

Where evidence is weak or mixed: Most over-the-counter sleep supplements (valerian, herbal blends) have limited and inconsistent evidence. Cannabis and CBD are popular but evidence is currently insufficient to recommend them. Consumer sleep trackers can support pattern awareness but are not validated to diagnose any sleep disorder. Generic “sleep hygiene” alone does not cure established chronic insomnia.

Spend effort first on the proven foundations. Add other things on top if you wish — not in place of them.

• GLP-1 and dual-agonist medications for sleep apnea in people with obesity. Tirzepatide, a dual GIP/GLP-1 receptor agonist, reduced the severity of breathing events substantially in the SURMOUNT-OSA trial.^[1] In the United States it has received FDA approval for moderate-to-severe OSA in adults with obesity. This is a real advance — but it is best understood as an addition to, not a replacement for, an accurate diagnosis and standard treatment. It does not remove the need for a sleep study or for follow-up testing.
• Hypoglossal nerve stimulation for selected sleep apnea. An implanted device that activates the nerve controlling the tongue during sleep, keeping the airway open. In carefully selected adults with moderate-to-severe OSA who cannot tolerate PAP, it has produced durable reductions in breathing events sustained over several years of follow-up (STAR trial).^[2] Eligibility depends on body weight, the specific pattern of airway collapse, and prior PAP intolerance.
• Digital CBT-I (prescription digital therapeutics). Well-designed app-based CBT-I programs deliver the actual active components of cognitive behavioral therapy for insomnia and some have been cleared by the FDA as prescription digital therapeutics. For people who cannot reach a trained CBT-I provider, a high-quality digital program is a legitimate route to first-line treatment. The key distinction: FDA-cleared programs deliver the real components; consumer “sleep apps” vary widely and should not be assumed equivalent.
• Newer approaches approaching approval. For narcolepsy, a new class of medications called orexin receptor agonists — which aim to replace the specific brain signal that is missing in narcolepsy type 1 — has completed pivotal Phase 3 trials. Oveporexton (TAK-861) by Takeda met all primary endpoints in its Phase 3 studies; the FDA accepted the New Drug Application with Priority Review in February 2026, with an action date targeted for Q3 2026 — meaning approval is possible this year. For obstructive sleep apnea, AD109 (aroxybutynin + atomoxetine) completed Phase 3 and an NDA has been submitted. Neither is approved for routine use yet, but a patient asking “is anything new coming?” should know the honest answer is yes — and soon.

What they are. Two slightly different sound frequencies played to each ear, creating a perceived “beat” at the difference frequency. The theory is that the brain’s electrical rhythms will synchronize with that beat and nudge the brain toward sleep.

What the research shows. Binaural beats have been studied in numerous trials and several systematic reviews. The evidence is consistently weak:

• A 2023 systematic review found that results across studies were inconsistent — roughly as many studies contradicted the entrainment idea as supported it.^[3]
• The best-designed randomized, double-blind, placebo-controlled trial found only minimal effects on sleep.^[4]
• Reviews of binaural beats for pain and stress have rated the overall quality of evidence as low to very low.^[5]

An honest bottom line. Binaural beats are inexpensive and low-risk. If listening to them is relaxing as part of a wind-down routine, there is no harm. What they are not is an evidence-based treatment for a sleep disorder, and they should not replace CBT-I or proper evaluation. The risk is not the audio itself — it is using it instead of a treatment that works.

A distinction worth knowing. Binaural beats should not be confused with closed-loop acoustic stimulation, a separate research field in which quiet sounds are delivered precisely timed to a person’s own brainwaves during deep sleep. That is a genuine area of investigation with a more credible mechanism, though still not a treatment patients can rely on today.

• Consumer sleep trackers and wearables. Useful for building awareness of patterns over time, which supports the conversation with a clinician. They are not validated to diagnose any sleep disorder. For some people, fixating on nightly scores actually increases sleep anxiety, which is counterproductive. Use them as a rough log, not a verdict.
• CBD and cannabis. Widely used for sleep, but the current evidence is insufficient to recommend them for a sleep disorder, and cannabis can alter sleep architecture. Discuss honestly with a clinician rather than self-treating.
• Over-the-counter sleep supplements (valerian, herbal blends). Limited and inconsistent evidence. Product quality varies because supplements are lightly regulated. Not a sound basis for managing a chronic sleep problem.
• OTC antihistamine sleep aids (diphenhydramine, doxylamine). Cause rapid tolerance, next-day grogginess, can worsen restless legs, and carry particular risk in older adults. Not a good long-term answer.

New sleep products appear constantly. Run any new claim through the same filter from the “Evaluating Sleep Claims” section above: Is it supported by randomized trials or a clinical guideline, or only by testimonials? Does it promise to fix many unrelated problems at once? Is it being offered instead of an accurate diagnosis?

The core principle: Spend your effort first on the treatments with the strongest evidence — CBT-I for insomnia, proper evaluation and treatment for sleep apnea, iron and the modern medication sequence for restless legs, correctly timed light and melatonin for circadian disorders. Add other things on top if you wish and they are low-risk. Never let an unproven product take the place of a proven one, or delay the diagnosis that tells you what you are actually treating.

A 2025 meta-analysis of 10 sham-controlled randomized controlled trials enrolling 757 patients found that acupuncture produced a statistically significant and clinically meaningful improvement in insomnia severity. The Pittsburgh Sleep Quality Index (PSQI) improved by a mean difference of −2.60 points (95% CI: −3.24 to −1.97, p<0.00001) compared with sham acupuncture.^[6]

What this means in practice: A PSQI reduction of 2.6 points is clinically meaningful — enough to move many patients from “poor” into “adequate” sleep quality. The sham-controlled design helps rule out placebo effects. Acupuncture is generally safe when performed by a licensed practitioner, with minor bruising as the most common side effect.

Limitations: Blinding in acupuncture trials is inherently imperfect. The effect size is moderate, not transformative. Acupuncture should be considered as a complement to first-line treatments (CBT-I for insomnia, PAP for sleep apnea), not a replacement.

Source: PMC12074954 — Meta-analysis of sham-controlled RCTs, 2025.

Orofacial myofunctional therapy is a structured exercise program that strengthens the muscles of the tongue, soft palate, and throat. Two independent 2024 meta-analyses found meaningful reductions in sleep apnea severity:

• Saba et al., Laryngoscope 2024: 7 RCTs, 310 patients — AHI (apnea-hypopnea index) reduction of −10.2 events/hour (95% CI: −15.6 to −4.8).^[7]
• A second meta-analysis found a similar AHI reduction of −9.54 events/hour, confirming the direction and magnitude of benefit.

What this means in practice: A reduction of 9–10 AHI events per hour is clinically significant, particularly for mild-to-moderate OSA. OMT is non-invasive, has no device requirement, and can be performed at home after initial instruction. It may be especially useful for patients who cannot tolerate CPAP or as a complement to other treatments.

Limitations: Requires consistent daily practice (typically 20–30 minutes). Benefits may diminish if exercises are stopped. Most trials enrolled adults; pediatric data is more limited. OMT does not replace CPAP for severe OSA.

Suanzaoren decoction (Suan Zao Ren Tang) is a classical Chinese herbal formula based on Ziziphus jujuba seeds. A systematic review and meta-analysis of 12 RCTs enrolling 1,311 patients published in the European Review for Medical and Pharmacological Sciences found:^[8]

• PSQI improvement of −3.35 points for combination therapy (suanzaoren decoction added to conventional treatment) and −1.94 points for monotherapy (suanzaoren decoction alone) vs. control.
• Insomnia recurrence reduced by approximately 50–53% (RR = 0.47) compared with control groups.

Important context: The stronger PSQI improvement (−3.35) was seen in combination therapy, not monotherapy. This means the decoction appears most effective when added on top of standard treatment, not used alone. The monotherapy benefit (−1.94 points) is more modest.

Limitations: Most included trials were conducted in China with variable methodological quality. Herbal products are not standardized internationally — composition and potency may vary between preparations. Potential herb-drug interactions should be reviewed with a pharmacist before use, especially with sedatives or other sleep medications.

Ashwagandha is an adaptogenic herb widely used in Ayurvedic medicine. A 2021 meta-analysis published in PLOS ONE pooled 5 RCTs with 1,764 participants and found a significant improvement in overall sleep quality:^[9]

• Standardized mean difference (SMD) = −0.59 (95% CI: −0.75 to −0.42), corresponding to a moderate effect size.
• Subgroup analysis showed stronger effects in adults with diagnosed insomnia compared with healthy volunteers, and in those taking ≥600 mg/day.

What this means in practice: An SMD of −0.59 is a moderate effect — comparable to some pharmaceutical sleep aids. Ashwagandha is generally well tolerated, with the most common side effects being mild gastrointestinal discomfort. Root extract preparations (KSM-66, Sensoril) were used in most trials.

Limitations: Trial sizes were modest. Long-term safety data beyond 8–12 weeks is limited. Rare cases of liver injury have been reported with high-dose or prolonged use. Should not replace CBT-I or evaluation for underlying sleep disorders. Product quality varies — choose third-party tested brands (USP, NSF, or ConsumerLab verified).

Source: PMC8462692 — Cheah KL et al., PLOS ONE 2021.

Consider talking to a clinician about your sleep if any of the following is true:

• Difficulty falling asleep, staying asleep, or waking too early occurs at least three nights a week and has lasted three months or more.
• Your sleep problem is clearly affecting your days — fatigue, low mood, irritability, poor concentration, reduced work performance, or strained relationships.
• You are sleepy enough during the day that it concerns you, or others have commented on it.
• You snore loudly, or someone has noticed you stop breathing, gasp, or choke during sleep.
• You have uncomfortable leg sensations or an urge to move your legs that interferes with relaxing in the evening or falling asleep.
• You rely on alcohol, over-the-counter sleep aids, or prescription sleeping pills to sleep.
• You have been managing on your own for a long time and it simply is not working.

For most sleep complaints, the primary care doctor is the right first stop. They can take a history, review medications, order initial blood tests, screen for sleep apnea, start treatment for straightforward insomnia, and refer onward when needed.

• Until you have been evaluated and the cause addressed, avoid driving when you feel sleepy. Do not rely on coffee, opening a window, or loud music — these do not restore safe alertness.
• Tell your clinician explicitly that this is happening. It changes the urgency of your evaluation.
• Severe, irresistible daytime sleepiness, with or without driving incidents, deserves prompt evaluation on its own.
• Several conditions — untreated sleep apnea, narcolepsy, severe insufficient sleep — can cause this and are treatable.

• Loud, habitual snoring, especially with witnessed pauses in breathing, gasping, or choking.
• Waking unrefreshed despite spending adequate time in bed; morning headaches; a very dry mouth on waking.
• Significant daytime sleepiness, particularly alongside high blood pressure that is hard to control, atrial fibrillation, or a history of stroke.

These warrant testing for OSA. Untreated moderate-to-severe OSA carries real cardiovascular and safety risk.

• Cataplexy: sudden, brief episodes of muscle weakness triggered by strong emotion — most classically laughter — such as the knees buckling, the head dropping, or the jaw going slack while remaining fully conscious. Cataplexy is highly specific and deserves prompt specialist referral.
• Sleep paralysis (briefly unable to move when falling asleep or waking) and vivid, dream-like hallucinations at sleep onset, especially together with severe sleepiness.
• Severe, persistent sleepiness in a younger person not explained by short sleep or shift work.

Dream-enactment behavior — shouting, punching, kicking, or leaping out of bed in response to a dream, sometimes injuring oneself or a bed partner — can indicate REM sleep behavior disorder, in which the normal muscle paralysis of REM sleep is absent. This deserves evaluation by a sleep specialist or neurologist. In middle-aged and older adults, REM sleep behavior disorder can precede certain neurological conditions by years; identifying it allows for monitoring and making the sleeping environment safe.

• Restless legs symptoms that begin suddenly, are severe from the outset, are markedly worse on one side, or are accompanied by numbness, weakness, or loss of sensation — these suggest a neuropathy or another secondary cause.
• New or worsening restless legs in pregnancy — common, often related to iron.
• Restless legs that have rapidly worsened, spread to the arms or daytime, or started occurring earlier in the day in someone already on a dopamine-type medication — this may indicate augmentation, an important complication covered in the treatment section.

• Sudden, severe insomnia with agitation, racing thoughts, and a reduced need for sleep — particularly with a history of bipolar disorder — should be discussed promptly with a clinician.
• Loud snoring or witnessed apneas in a child, along with restless sleep, mouth-breathing, or daytime behavioral problems — pediatric OSA is treatable.
• Excessive sleepiness after starting a new medication — review with the prescriber.

• Start a sleep diary now — two weeks of simple daily records is the single most useful thing you can bring. Memory is unreliable for sleep; a diary replaces guesswork with data.
• Prepare a complete medication and supplement list — including over-the-counter products, herbal supplements, and caffeine and alcohol habits.
• Involve the person who shares your bed or home. They see things you cannot: snoring, breathing pauses, leg kicking, acting out dreams. A bed partner’s observations are genuine diagnostic information.
• Write down your questions in advance. Clinicians welcome a prepared patient. A focused list makes a short visit far more productive.
• If you sleep alone, a single audio or video recording of a night’s sleep on your phone can be surprisingly informative. Record only yourself, or others with their consent.

• Started a sleep diary — recording bedtime, sleep onset, awakenings, wake time, naps, caffeine, alcohol, and subjective quality every morning
• Completed the STOP-BANG questionnaire to self-screen for obstructive sleep apnea risk
• Completed the Insomnia Severity Index (ISI) to quantify insomnia
• Completed the Epworth Sleepiness Scale (ESS) to quantify daytime sleepiness
• Prepared a full medication and supplement list (including over-the-counter products)
• Asked bed partner or family member about snoring, breathing pauses, leg movements, or acting out dreams
• Written down main sleep complaints, their duration, and their daytime impact
• Written a short list of questions for the first appointment

• Primary care appointment scheduled or completed
• Blood tests ordered if indicated (iron studies, thyroid function, complete blood count, glucose)
• Sleep study ordered if indicated (home sleep apnea test or in-lab polysomnography)
• CBT-I provider or digital program identified if insomnia is the main problem
• Sleep specialist referral requested if diagnosis is uncertain or complex
• Immediate “free wins” claimed: consistent wake time, morning light, caffeine moved earlier, alcohol separated from bedtime
• Safety addressed: not driving while drowsy; sleep environment made safe if dream-enactment behavior is present

Your clinician will order either an in-lab polysomnography (PSG) or a home sleep apnea test (HSAT). For most otherwise healthy adults with a high clinical suspicion of OSA and no significant comorbidities, a home test is a reasonable and validated starting point — it is less expensive, faster to access, and well-studied. An in-lab study is preferred when there is concern about other sleep disorders (REM sleep behavior disorder, periodic limb movements), significant cardiac or respiratory disease, or when the home test result is negative despite strong clinical suspicion.

The key number from your study is the apnea-hypopnea index (AHI) — the average number of breathing pauses and partial obstructions per hour of sleep:

• AHI 5–14: Mild OSA. Symptoms and cardiovascular risk factors determine how aggressively to treat.
• AHI 15–29: Moderate OSA. Treatment is generally recommended for all patients.
• AHI ≥30: Severe OSA. Prompt treatment is strongly advised.

The AHI alone does not tell the whole story. Oxygen desaturation events — how low oxygen drops during apneas — and the degree of sleep fragmentation are also relevant to your long-term cardiovascular and cognitive risk. Your report may also include the oxygen desaturation index (ODI), which captures how many times per hour your blood oxygen drops significantly.

For moderate-to-severe OSA, and for mild OSA with significant symptoms or cardiovascular risk, auto-titrating positive airway pressure (APAP) is the most common starting therapy. The machine adjusts pressure breath by breath within a set range (typically 4–20 cmH₂O), adapting to body position, sleep stage, and airway changes. Most people do not need a manual pressure-titration study first — APAP data guides ongoing pressure optimization.

What to expect in the first two weeks:

• Mask fit takes a few adjustments. Nasal pillows, nasal masks, and full-face masks are all options — the right fit is the one that seals well without significant leak and that you can wear all night.
• Heated humidification and heated tubing dramatically reduce the nasal dryness and condensation (“rainout”) that cause people to give up. These should be turned on from the start.
• The “ramp” setting starts at low pressure and builds gradually so you can fall asleep comfortably. Use it if getting used to the pressure at full level is difficult.
• Your machine uploads data nightly via cellular or Wi-Fi. Review this with your provider: it shows hours of use, residual AHI on therapy (target fewer than 5 events per hour = adequate control), and mask leak. Most CPAP users can also access their own data through manufacturer apps such as ResMed myAir.

A follow-up appointment at one to three months is standard. Your clinician will:

• Review the downloaded device data (usage hours, residual AHI, leak data)
• Ask about symptom improvement — daytime sleepiness, partner reports on snoring, morning headaches
• Troubleshoot any ongoing mask, pressure, or dryness issues
• Adjust the pressure range or mode if residual AHI is still elevated (above 5 events per hour suggests therapy is not fully controlling the apnea)

OSA is the most common identifiable cause of drug-resistant hypertension. If you have blood pressure that is difficult to control on multiple medications, effective OSA treatment typically reduces systolic blood pressure by 2–3 mmHg — modest in absolute terms but meaningful when you are already on multiple antihypertensive agents. Your cardiologist or primary care physician should know you are being treated for OSA.

Screen for COMISA. Insomnia and OSA frequently coexist (a pattern called COMISA — comorbid insomnia and sleep apnea). If you are using your PAP device adequately but still cannot sleep well or feel unrefreshed, ask your provider about being evaluated for insomnia. The current evidence supports treating both simultaneously, with CBT-I starting at the same time as PAP therapy, rather than treating one and hoping the other resolves on its own.

For a meaningful minority of people, PAP therapy is genuinely intolerable despite a full effort. If you have tried mask refitting, humidification adjustments, pressure ramping, and a few weeks of persistence but still cannot use the device, you have real alternatives — not just consolation options.

• Oral appliance therapy (mandibular advancement device, MAD): A custom dental device, fitted by a dentist with sleep-medicine training, that holds the lower jaw slightly forward, widening the upper airway. Well-established for mild-to-moderate OSA and for people with more severe OSA when PAP has genuinely failed. Slightly less effective than PAP for severe OSA on average, but effectiveness depends on anatomy. Requires follow-up sleep testing to confirm adequate control.
• Hypoglossal nerve stimulation (Inspire therapy): A surgically implanted device that monitors breathing and delivers a small electrical impulse to move the tongue forward during sleep, preventing airway collapse. FDA-approved for adults with moderate-to-severe OSA who are intolerant to CPAP and meet specific anatomical criteria (BMI below a certain threshold, no complete concentric collapse of the palate on drug-induced sleep endoscopy). Available at the University of Utah ENT and Sleep Surgery program and at most large academic sleep centers nationally.
• Weight loss as a disease modifier: If BMI is above 30, every 10% reduction in body weight produces approximately 26% improvement in AHI on average. Tirzepatide (Zepbound), now FDA-approved specifically for moderate-to-severe OSA with obesity, may accelerate this process substantially. Weight loss does not replace PAP in the short term but can reduce or resolve OSA over time — with follow-up sleep testing to confirm.
• Upper airway surgery: Procedures such as uvulopalatopharyngoplasty (UPPP) have moderate and variable evidence — they work well in carefully selected patients but require thorough anatomical evaluation first. Surgical outcomes are best when anatomy clearly predicts the obstruction site.
• Positional therapy: If your sleep study shows OSA is significantly worse in the supine (back-sleeping) position, devices that discourage back sleeping are a low-risk adjunct or monotherapy for positional OSA.

OSA is a chronic condition for most adults — it does not go away without a structural change (weight loss, surgery, or anatomical changes with age). The main tasks of long-term management are:

• Sustain PAP use. Adherence tends to decline slightly after the first year. Regular equipment maintenance (replacing mask cushion every 1–3 months, headgear every 6 months, filters monthly) keeps therapy comfortable and effective.
• Respond to weight changes. Weight gain can worsen OSA severity and may require upward pressure adjustment. Significant weight loss may mean lower pressure requirements — and warrants a reassessment.
• Annual or biannual follow-up. Review symptoms, check device data, and update the care plan. Repeat sleep study is generally not needed if device data shows adequate control — but may be warranted after major weight change, surgery, or new symptoms.
• Inform your full care team. Your cardiologist and primary care physician should both know about your OSA diagnosis and treatment status. Treated OSA is part of your overall cardiovascular risk management strategy.

• Sleepy or fighting to stay awake while driving? Treat this as urgent. Stop driving while drowsy and seek prompt evaluation, whatever else is going on.
• Loud snoring, witnessed breathing pauses, gasping, or unrefreshing sleep — especially with high blood pressure? Point toward an obstructive sleep apnea evaluation.
• Difficulty falling or staying asleep at least three nights a week for three months or more? Point toward the insomnia pathway and CBT-I — but screen for apnea, restless legs, and a circadian cause first.
• An urge to move the legs, worse at rest and in the evening, relieved by movement? Point toward the restless legs pathway: iron studies and a medication review.
• Sleep itself is fine — just at the “wrong” hours? (For example, unable to sleep until 2–4 a.m. but fine on a free schedule.) Point toward a circadian rhythm disorder.
• Sudden muscle weakness with emotion, sleep paralysis, dream-like hallucinations at sleep onset, or acting out dreams? Point toward specialist evaluation.

Overlap is the rule, not the exception. If two of these fit, start with the safety item first, then work through the diagnostic pathway — it is designed to sort out exactly this.

• The time you got into bed, and the time you tried to fall asleep (these are often different).
• Roughly how long it took to fall asleep (sleep latency).
• The number and rough length of any awakenings during the night.
• Your final wake-up time, and the time you actually got out of bed.
• Any naps during the day, with their length.
• Caffeine and alcohol — how much, and when.
• Exercise, and any sleep medication or aid used.
• A simple rating of sleep quality and of how you felt during the day.

Sleep latency — how long it takes to fall asleep. Persistently long latency points toward sleep-onset insomnia, restless legs, or a delayed body clock.

Sleep efficiency — the percentage of time in bed that is actually spent asleep (time asleep divided by time in bed, multiplied by 100). Healthy sleep efficiency is roughly 85 percent or higher. A low number — lots of time in bed, much of it awake — is a hallmark of insomnia and is the specific target of the sleep restriction component of CBT-I.

Free printable diary templates are available from the American Academy of Sleep Medicine’s patient site and the Sleep Foundation. A wearable tracker can supplement a diary but should not replace it — consumer trackers estimate sleep stages imperfectly, and for some people, fixating on nightly scores increases sleep anxiety.

The ISI is a 7-item questionnaire measuring the severity of insomnia symptoms and their daytime impact. It is used to track insomnia over time, and a drop of several points represents a meaningful treatment response.

Score interpretation:

• 0–7: No clinically significant insomnia.
• 8–14: Subthreshold insomnia — may benefit from behavioral adjustments.
• 15–21: Moderate clinical insomnia — warrants formal treatment such as CBT-I.
• 22–28: Severe clinical insomnia.

The ESS asks how likely you are to doze off in eight everyday situations, scored 0 to 24. It screens for excessive daytime sleepiness.

Score interpretation:

• 0–10: Normal daytime sleepiness.
• 11–12: Mild excessive sleepiness — worth raising with a clinician.
• 13–15: Moderate excessive sleepiness — medical evaluation recommended.
• 16–24: Severe excessive sleepiness — a red flag; prompt evaluation for OSA or narcolepsy.

STOP-BANG screens for the risk of obstructive sleep apnea using eight yes/no items: Snoring, Tiredness, Observed apneas, Pressure (high blood pressure), BMI, Age, Neck circumference, and Gender.

Score interpretation:

• 0–2: Low risk for OSA.
• 3–4: Intermediate risk — consider a sleep study.
• 5–8: High risk — strongly supports proceeding to a sleep study.

The IRLS is a 10-item questionnaire that confirms the severity of restless legs symptoms and tracks response to treatment.

Score interpretation:

• 1–10: Mild restless legs.
• 11–20: Moderate — warrants medical assessment and iron studies.
• 21–30: Severe.
• 31–40: Very severe.

These reference ranges are aids to conversation, not diagnoses — only a clinician can interpret them in your particular context.

• Iron studies — essential for anyone with suspected restless legs. The workup should include ferritin (a measure of iron stores) and transferrin saturation. Standard blood counts can look completely normal while iron stores are low. Best practice: draw iron studies in the morning, fasting, having avoided iron-containing food and supplements for about 24 hours beforehand.
• Thyroid function — both underactive and overactive thyroid can disturb sleep and energy.
• Complete blood count — to check for anemia as a cause of fatigue.
• Glucose or HbA1c — given the two-way relationship between sleep and metabolic health.
• Kidney function, vitamin B12, and others as indicated — kidney disease and certain deficiencies can drive restless legs and neuropathy.

A medication review is part of every sleep evaluation. A surprising number of sleep complaints are caused or worsened by something already on the medication list, by alcohol, or by caffeine. Common culprits include:

• Stimulating antidepressants (some SSRIs/SNRIs, bupropion) — can delay sleep onset, especially if taken later in the day; SSRIs/SNRIs can also worsen RLS.
• Sedating antihistamines (diphenhydramine, doxylamine) — can trigger or worsen restless legs.
• Beta-blockers — can cause insomnia and vivid dreams.
• Corticosteroids — activating; can cause difficulty falling asleep.
• Decongestants — stimulant effect that can delay sleep.
• Diuretics taken late — cause nighttime urination.
• Opioids and sedatives — can worsen sleep-disordered breathing.
• Alcohol — speeds sleep onset but fragments sleep and worsens snoring and apnea.

A home sleep apnea test is a simplified study done in your own bed with a small device that typically records airflow, breathing effort, oxygen levels, and heart rate. It is appropriate for adults with a high likelihood of moderate-to-severe OSA who do not have significant heart or lung disease.

It is convenient and lower in cost, and insurers often prefer it as the first test. Its main limitation is that it can underestimate severity and does not evaluate other sleep disorders, so a negative home test in a strongly symptomatic person is often followed by an in-lab study.

An in-lab polysomnogram is the comprehensive overnight study, recording brain waves (sleep stages), eye and muscle activity, airflow and breathing effort, oxygen, heart rhythm, and leg movements. It is the appropriate test when:

• There is significant heart, lung, or neuromuscular disease, or central sleep apnea is suspected.
• A home test was negative but suspicion remains high, or was technically inadequate.
• A non-breathing disorder is suspected — periodic limb movement disorder, REM sleep behavior disorder, or unexplained nighttime events.
• Narcolepsy or idiopathic hypersomnia is suspected (paired with the MSLT the next day).

Multiple Sleep Latency Test (MSLT): A daytime test performed after an in-lab polysomnogram. A series of scheduled nap opportunities measures how quickly you fall asleep and whether you enter REM sleep rapidly — helping diagnose narcolepsy and idiopathic hypersomnia. It must be set up carefully with adequate sleep beforehand and a clear medication review.

Maintenance of Wakefulness Test (MWT): Measures the opposite — how well you can stay awake in a quiet setting. Used more for gauging treatment response and assessing fitness for safety-critical activities like driving.

Actigraphy: A wrist-worn device worn for one to several weeks to estimate sleep and wake patterns over time. Particularly useful for circadian rhythm disorders and confirming suspected insufficient sleep. It complements, rather than replaces, a sleep diary.

• Ask what to do about medications and substances — whether to continue or hold any, and whether to limit caffeine, alcohol, sleeping aids, or cannabis.
• Keep your routine the night before — aim for your usual sleep, avoid napping, and skip caffeine after about noon.
• Bring a current medication and supplement list, comfortable sleepwear, toiletries, and your own PAP mask or oral appliance if you already use one.
• Ask the logistics questions up front: when and how you will get results, who will interpret them, and your expected out-of-pocket cost.
• For a home test, follow the device instructions carefully — a technically inadequate study often has to be repeated.

• Many insurers require a home sleep apnea test before authorizing an in-lab study for suspected uncomplicated OSA. Knowing this in advance prevents surprise denials.
• Sleep studies and CBT-I are generally covered when ordered for an appropriate indication, but coverage details, prior-authorization rules, and in-network requirements vary widely.
• If referred for a sleep study, choose an accredited facility where possible. The AASM maintains a directory of accredited sleep centers.
• Ask the ordering clinic’s staff to confirm coverage before the study.

Stimulus control retrains the brain to associate the bed with sleep rather than wakeful frustration:

• Go to bed only when you are genuinely sleepy — not merely tired or bored.
• Use the bed only for sleep and sex. No working, scrolling, worrying, or watching television in bed.
• If you are awake and frustrated for roughly 20 minutes (estimated, not clock-watched), get up, leave the bedroom, and do something quiet in dim light until sleepy again. Repeat as needed.
• Keep one fixed wake-up time every day, including weekends, regardless of how the night went. The wake time is the anchor that stabilizes the whole system.
• Do not nap, at least early in treatment, because napping spends the sleep drive you are trying to build.

Sleep restriction is the most effective single component of CBT-I and also the most counterintuitive. People with insomnia tend to spend far more time in bed than they actually sleep, hoping to “catch” sleep — which dilutes sleep across the night and deepens the wakefulness association. Sleep restriction deliberately limits time in bed to roughly match the time you are actually sleeping, building strong sleep drive and consolidating sleep into a solid block. As sleep efficiency rises, time in bed is gradually expanded.

The weekly rhythm:

• Set the baseline: From one to two weeks of diary data, calculate your average total sleep time.
• Set the first window: Time in bed is set to roughly match that average, with a fixed bedtime and wake time — never reduced below about 5 to 5.5 hours.
• Hold for a week: Track sleep efficiency each morning.
• If efficiency is above ~85–90%: extend time in bed by about 15–20 minutes.
• If efficiency is below ~80–85%: trim time in bed by about 15–20 minutes (respecting the floor).
• If in between: hold unchanged and reassess the next week.
• Repeat: expand gradually toward your full sleep need as sleep consolidates.

The cognitive component targets the beliefs and worry patterns that keep the arousal system switched on:

• Catastrophic thinking — “if I don’t sleep I won’t function at all tomorrow.” These predictions are usually exaggerated; examining them calmly reduces the anxiety that itself prevents sleep.
• Unrealistic expectations — the belief that everyone sleeps eight unbroken hours, or that any awakening is a failure.
• Sleep effort — the paradox that trying hard to sleep guarantees wakefulness. Techniques shift the goal from “make myself sleep” to “allow rest.”
• Racing mind — scheduled “worry time” earlier in the evening, writing down concerns and any next steps, keeps problem-solving out of the bedroom.

Relaxation training: Techniques such as slow diaphragmatic breathing, progressive muscle relaxation, and guided imagery lower physical and mental arousal. They are most useful for people whose insomnia is driven by tension. They are practiced as skills — built up during the day, not summoned in a panic at 3 a.m.

Sleep hygiene: The everyday habits that support sleep — consistent timing, limiting caffeine and alcohol, a dark and cool bedroom, a wind-down routine. These matter, but sleep hygiene alone does not cure established chronic insomnia. It is the supportive layer beneath CBT-I, not a substitute for it. Being told to “just practice good sleep hygiene” is one of the most common reasons people with genuine insomnia fail to improve.

Timeline: Most people notice change within two to four weeks of consistent CBT-I, with fuller benefit by six to eight weeks. Success means falling asleep faster, spending less time awake at night, sleep efficiency rising to roughly 85% or above, better daytime function, and far less anxiety about sleep.

Accessing CBT-I: Several routes exist:

• A behavioral sleep medicine specialist or psychologist trained in CBT-I — the gold standard. The Society of Behavioral Sleep Medicine maintains a provider directory.
• Digital CBT-I programs — well-designed app- and web-based programs with good evidence. Some are FDA-cleared.
• Primary care-delivered or brief versions, group CBT-I, and telehealth CBT-I.
• If no provider is genuinely available and digital programs are unaffordable: Ask your primary care doctor about brief behavioral treatment for insomnia (BBTI) — a condensed, 4-session version that can be delivered by a trained nurse or primary care provider. It focuses on the two most powerful components (sleep restriction and stimulus control) and produces meaningful improvement even without a specialist.

When medication has a role: Medication is reasonable as a short-term measure during an acute episode, when CBT-I is not yet available, or as a temporary adjunct alongside CBT-I. The principle is the lowest effective dose for the shortest reasonable duration, with a plan for tapering, and with CBT-I doing the durable work underneath.

Before any RLS-specific medication, the first step is to identify and remove or reduce things that provoke or worsen symptoms. For milder RLS, this step alone can be enough:

• Substances: alcohol, caffeine, and nicotine commonly aggravate RLS.
• Sedating antihistamines: diphenhydramine (found in many OTC sleep aids) is a frequent and often unrecognized trigger. People with RLS sometimes take an antihistamine sleep aid for sleeplessness and unknowingly worsen the problem.
• Certain antidepressants: many serotonergic antidepressants (SSRIs and SNRIs) and mirtazapine can worsen RLS. This does not mean stopping a needed antidepressant — it means raising the interaction with your clinician. Bupropion is generally less likely to aggravate RLS.
• Anti-nausea medications: metoclopramide and prochlorperazine can provoke or worsen RLS.
• Untreated sleep apnea and chronic sleep deprivation both worsen RLS.

Iron is central to RLS biology, and iron repletion is a first-line treatment — not an afterthought. Serum iron studies including ferritin and transferrin saturation should be checked in everyone with clinically significant RLS, and rechecked periodically.

When iron is given: A trial of oral iron is appropriate when iron stores are low or low-normal — commonly when ferritin is at or below roughly 75 ng/mL, or when transferrin saturation is clearly low. Intravenous iron is considered in selected patients when oral iron is not suitable, not tolerated, or when faster repletion is needed.

• Moderate regular exercise is associated with fewer RLS symptoms; intense exercise very close to bedtime may aggravate symptoms.
• Peroneal nerve stimulation: a wearable device delivering stimulation to the peroneal nerves at the knees, used in the evening. Recognized by the 2025 AASM guideline as a non-drug option for adults with RLS.
• Pneumatic compression, counterstimulation (massage, stretching, warm or cool applications), and engaging the mind with an absorbing activity during enforced rest can provide relief.
• Good sleep habits, since sleep deprivation worsens RLS and creates a vicious cycle.

The modern approach has shifted significantly. For years, dopamine agonists (pramipexole, ropinirole, rotigotine patch) were the standard first choice. They work quickly, but long-term use carries the serious problem of augmentation, and the 2025 AASM guideline no longer recommends them as first-line therapy.

The current first-line medication class is the alpha-2-delta ligands (gabapentinoids): gabapentin enacarbil as a first-line option, with gabapentin and pregabalin as alternatives. These drugs do not cause augmentation, often help coexisting sleep disturbance and pain, and have become the preferred starting point.

Dopamine agonists are no longer first-line; their use is more limited and individualized. They are effective short-term but carry augmentation risk with long-term use, as well as impulse-control side effects.

Low-dose extended-release opioids are a conditional option for severe, refractory RLS, under specialist supervision.

Augmentation is the central reason dopamine agonists were downgraded from first-line. If you are on a dopamine agonist and your RLS seems to be worsening, spreading, or starting earlier in the day, do not simply increase the dose. Contact your clinician promptly; managing augmentation usually means a careful, supervised transition to a different class of treatment.

Positive airway pressure (PAP) therapy is the first-line treatment for moderate-to-severe OSA. A small bedside machine delivers gently pressurized air through a mask, acting as a pneumatic splint that holds the airway open. Common forms include CPAP (continuous pressure), APAP (auto-adjusting), and BiPAP (different pressures for breathing in and out).

When used consistently, PAP effectively abolishes most breathing events, restores sleep continuity, and typically improves daytime sleepiness, blood pressure, and quality of life. PAP’s most consistent benefits are reducing breathing events, improving overnight oxygen, restoring sleep continuity, and reducing daytime sleepiness. The evidence for preventing hard cardiovascular events is more mixed and depends on consistent use.

Adherence is the whole game. PAP only works on the nights and hours it is actually worn. Benefit is dose-dependent — more hours of use, more benefit. The first few weeks are an adjustment period, and this is where many people give up unnecessarily. The encouraging reality is that the early obstacles are almost all solvable.

• Mask fit is the most common make-or-break factor. There are nasal masks, nasal pillows, and full-face masks; finding the right type and size is worth real persistence. A leaking or ill-fitting mask is the leading reason people abandon therapy — and it is fixable.
• Use the comfort features. A “ramp” setting starts at low pressure and builds gradually. Heated humidification prevents dryness and nasal congestion. Both should be set up for you.
• Expect an adjustment period. Wearing the mask for short stretches while awake helps desensitize you. Most people who push through two to four weeks adapt well.
• Use the data. Modern machines report nightly usage, residual AHI, and mask leak. Reviewing this with your clinician turns troubleshooting into a solvable problem.
• Ask for help early. Equipment suppliers and sleep clinics have staff whose job is exactly this. Persistent problems deserve a clinic visit, not surrender.

• Oral appliance therapy: A custom dental device (mandibular advancement device) that holds the lower jaw slightly forward, widening the airway. An established option for mild-to-moderate OSA, and for people with more severe OSA who cannot tolerate PAP. Best fitted by a dentist with sleep-medicine training, with follow-up testing.
• Weight management: Excess weight is a major modifiable risk factor; weight loss can substantially reduce OSA severity. Tirzepatide (a dual GIP/GLP-1 receptor agonist) has been approved by the FDA specifically for moderate-to-severe OSA in adults with obesity, used alongside diet and exercise. It is best understood as an adjunct, not a reason to skip testing or follow-up.
• Positional therapy: Devices and techniques that discourage sleeping on the back, for people whose OSA is primarily position-dependent.
• Hypoglossal nerve stimulation: An implanted device for selected adults with moderate-to-severe OSA who cannot tolerate PAP and meet specific criteria.
• Surgery: Procedures addressing the tonsils, soft palate, nasal passages, or jaw structure help in carefully selected cases — particularly in children, where enlarged tonsils and adenoids are a common cause and removal is often curative.
• Treating contributors: Alcohol and sedatives relax the airway; nasal congestion makes PAP harder to use. Addressing these supports whatever primary treatment you use.

Commercial drivers and people in safety-critical roles have specific regulatory considerations around conditions like untreated OSA. Be honest with your clinician; treated OSA is generally compatible with these jobs, whereas untreated OSA is the real hazard. Treating the underlying disorder restores safe daytime alertness for the large majority of people.

In December 2024, the FDA approved tirzepatide (Zepbound) — a GIP/GLP-1 receptor agonist — as the first medication specifically approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity. This represents a landmark approval: it is the first pharmacologic treatment targeting OSA itself, not merely its symptoms.

• Mechanism: Tirzepatide promotes significant weight loss by activating both GIP and GLP-1 receptors, reducing the excess upper airway tissue that causes airway collapse during sleep.
• Evidence: The SURMOUNT-OSA Phase 3 trials showed tirzepatide reduced AHI (apnea-hypopnea index) by up to 62% compared to placebo — moving many patients out of the moderate-to-severe category.
• Who it is for: Adults with moderate-to-severe OSA AND obesity (BMI ≥30). Intended to be used alongside PAP therapy — PAP remains first-line for OSA regardless of weight.
• Important: Tirzepatide is the same active ingredient as Mounjaro (for type 2 diabetes). Do not use Mounjaro for OSA — it has a different FDA-approved indication.
• Side effects: Nausea, vomiting, diarrhea (common initially, usually improve). Requires weekly subcutaneous injection.

Why it matters: For patients with both obesity and OSA who struggle with PAP adherence, tirzepatide addresses one of OSA’s root causes. It may also improve cardiovascular and metabolic outcomes. Insurance prior authorization is typically required; discuss access with your care team.

In central sleep apnea, breathing pauses occur without any physical obstruction. There is no snoring, no respiratory effort against a blocked airway — the drive to breathe simply fails briefly. Central apneas are most commonly seen in:

• Heart failure: Particularly as Cheyne-Stokes respiration, a distinctive pattern where breathing follows a crescendo-decrescendo cycle — building to rapid breathing then tapering to apnea and back. Central sleep apnea with Cheyne-Stokes respiration is present in 25–40% of people with heart failure with reduced ejection fraction (HFrEF).
• Opioid medications: Opioids suppress the brain’s respiratory drive during sleep and can cause irregular, ataxic breathing with frequent central apneas. The risk increases with opioid dose and is higher with long-acting formulations.
• High altitude: At altitude, reduced oxygen triggers hyperventilation, which lowers carbon dioxide below the threshold that drives the next breath — a temporary pause follows. This is normal physiology at high altitude, resolves with acclimatization, and does not require treatment in healthy people.
• Neurological conditions: Stroke, brainstem lesions, and certain neuromuscular conditions can impair the brain’s control of breathing during sleep.
• Idiopathic (primary) CSA: No identifiable cause; relatively uncommon.

A specific and important scenario: some people, after starting PAP therapy for obstructive sleep apnea, develop central apneas that were not present on their pre-treatment diagnostic study. This is called treatment-emergent central apnea (TECA), previously called complex sleep apnea syndrome.

The good news: in the majority of cases, TECA resolves on its own within one to three months as the airway and respiratory control system adapt to PAP therapy. No change in treatment is needed beyond monitoring and reassurance. If central apneas persist beyond three months and are causing symptoms, switching to an ASV (adaptive servo-ventilation) device — which provides variable pressure support matched to breathing effort — is the standard approach.

CSA requires an in-lab polysomnography (PSG) for accurate diagnosis — home sleep tests are not designed to reliably classify central versus obstructive events. Treatment depends entirely on the underlying cause:

• Heart failure-related CSA: Optimizing heart failure medications (ACE inhibitors or ARBs, beta-blockers, diuretics, SGLT2 inhibitors where appropriate) is the most important step and often substantially reduces CSA. Cardiac resynchronization therapy (CRT) can significantly reduce CSA in eligible heart failure patients. CPAP may help any coexisting obstructive component. ASV is contraindicated when EF is at or below 45%.
• Opioid-related CSA: Reducing opioid dose when medically feasible is the most effective intervention. PAP therapy can reduce opioid-related CSA when opioid reduction is not possible or sufficient.
• Idiopathic CSA: CPAP or ASV (in people with normal ejection fraction) may help. Acetazolamide, a medication that mildly stimulates breathing, is sometimes used in selected cases.
• TECA: Monitor and wait (resolves in the majority within 1–3 months). If persistent and symptomatic after three months, evaluate for ASV after verifying normal ejection fraction.

If a sleep study shows significant central apneas, the underlying cause deserves investigation. Central sleep apnea is often a marker of an important systemic condition — especially heart failure — and should prompt a thoughtful clinical workup beyond the sleep disorder itself.

The internal clock runs late: the person is a confirmed “night owl” who is not sleepy until the small hours and naturally inclined to wake late morning. Forced into conventional hours, they look as if they have sleep-onset insomnia at night and excessive sleepiness in the morning. It is common in adolescents and young adults and has a biological basis — it is not laziness.

Treatment combines timed light and timed melatonin, plus gradual schedule adjustment:

• Morning bright light soon after the desired wake time pulls the clock earlier.
• Low-dose melatonin taken in the evening, well before the current sleep time (typically several hours before), nudges the clock earlier. Timing matters more than dose for circadian use.
• Bright light late at night does the opposite and should be limited.
• This is best done with clinician guidance, because mistimed light or melatonin can move the clock the wrong way.

The mirror image: the clock runs early, with sleepiness in the early evening and waking in the very early morning hours. More common with age. Treatment reverses the strategy — bright light exposure in the evening to hold the clock later, and care to avoid bright morning light too early.

When work hours conflict with the body clock, the result is insomnia during scheduled sleep, sleepiness during work, or both. The body clock resists permanent adjustment, especially with rotating shifts. Realistic strategies include:

• Protecting a consistent, sufficient sleep period as a scheduled priority, with a dark, quiet, cool bedroom.
• Using light strategically: bright light during the work shift, darkness (including dark sunglasses on the commute home) before daytime sleep.
• Timed caffeine for alertness early in the shift, avoided in the second half.
• A planned nap before or during a night shift to reduce sleepiness.
• Discussing melatonin and, in some cases, a wake-promoting medication with a clinician.
• Where possible, favoring forward-rotating shift schedules (day to evening to night) and longer runs on one shift.

Jet lag: Temporary misalignment after crossing time zones. Begin shifting your schedule toward the destination a few days before travel; on arrival, seek or avoid light at the times that pull your clock in the needed direction; use melatonin timed to the destination night; adopt local meal and sleep times promptly. Eastward travel is generally harder to adjust to.

Non-24-hour sleep-wake rhythm disorder: The body clock fails to lock onto the 24-hour day and drifts later each day. Most common in people who are totally blind. Melatonin taken at a fixed clock time can help re-anchor the rhythm.

Irregular sleep-wake rhythm disorder: No single main sleep period; sleep is scattered across the 24 hours. Most often seen with significant neurological conditions. Structured daytime light exposure and consistent activity schedules are the mainstays.

Narcolepsy is a lifelong condition, but with the right combination of medication and behavioral adjustments, most people live productive lives.

• For daytime sleepiness: Wake-promoting medications (modafinil, armodafinil) are usually tried first. They help you stay alert without the “wired” feeling of traditional stimulants. Solriamfetol is a newer option with strong trial data. Traditional stimulants (methylphenidate, amphetamines) may be added if needed.
• For cataplexy (type 1): Sodium oxybate (Xyrem) or low-sodium oxybate (Xywav) taken at bedtime is the most effective treatment. It is the only medication that addresses sleepiness, cataplexy, and disrupted nighttime sleep all at once. It requires careful dose titration. A newer formulation, once-nightly extended-release sodium oxybate (Lumryz, by Avadel), removes the need for a middle-of-the-night redose. Pitolisant (a non-scheduled medication) and certain antidepressants (venlafaxine, fluoxetine) also reduce cataplexy.
• Behavioral strategies: Scheduled short naps (15–20 minutes, one or two per day) are genuinely therapeutic in narcolepsy — they are part of the treatment plan, not a sign of failure. Regular sleep-wake schedules, exercise, and avoiding heavy meals during the day help.
• Driving and safety: Discuss driving fitness with your sleep specialist. Many people with well-treated narcolepsy drive safely. The key is achieving adequate wakefulness on treatment and honest self-assessment.
• Emerging — Oveporexton (TAK-861): An orexin receptor agonist designed to replace the wake-signaling brain chemical missing in narcolepsy type 1. The pivotal Phase 3 studies FirstLight (NCT06470828) and RadiantLight (NCT06505031) met all primary endpoints in 2025. The FDA accepted the New Drug Application with Priority Review in February 2026; PDUFA target date Q3 2026. If approved, it would be the first orexin-replacement therapy for narcolepsy type 1. Not yet approved anywhere as of June 2026.

Idiopathic hypersomnia (IH) is characterized by excessive sleep need (often 10–14 hours), severe difficulty waking (“sleep drunkenness”), and unrefreshing naps — distinguishing it from narcolepsy, where naps are typically refreshing.

• Diagnosis: Requires a sleep study and daytime testing (MSLT) to exclude other causes. The diagnosis can be challenging because there is no single definitive test — it relies on the overall pattern.
• Treatment: Modafinil and armodafinil are usually tried first for wakefulness. Low-sodium oxybate (Xywav) received the first FDA approval specifically for idiopathic hypersomnia in 2021 — a significant milestone. Stimulants may be needed for severe cases.
• Practical realities: Many IH patients need alarm clocks with escalating features, a willing partner or family member to help with wake-up, and workplace accommodations (flexible start times, structured nap breaks). The condition is real, recognized, and not laziness.

In normal REM (dreaming) sleep, the body is temporarily paralyzed — a protective mechanism that keeps the sleeping person still while the brain is actively dreaming. In RBD, this protective muscle paralysis is absent or significantly reduced. The sleeper acts out dream content: talking, shouting, laughing, gesturing, punching, kicking, leaping, or falling out of bed. Bed partners are sometimes injured. The person typically recalls a vivid, action-filled dream that directly corresponds to the observed behavior.

Common features that partners and family members report:

• Sudden, complex movements or vocalizations during sleep, typically in the second half of the night (when REM sleep is most concentrated)
• Vivid, often frightening or action-themed dreams that the person recalls clearly on waking
• Risk of injury — to the person with RBD or to the bed partner
• The person typically becomes alert and oriented quickly after being awakened — in contrast to sleepwalking, which occurs in NREM sleep and is associated with confusion and amnesia on waking

How it is confirmed: RBD requires an overnight video-polysomnography (PSG) to diagnose accurately. The study documents REM sleep without atonia (RWA) — the measurable hallmark on the EMG channels — and the video component may capture enacted behaviors directly. A home sleep test cannot diagnose RBD. Referral to a sleep medicine specialist or neurologist is appropriate when the history is suggestive.

This is the most important thing to understand about RBD in adults: isolated RBD in a middle-aged or older adult is a powerful predictor of synucleinopathy — the family of neurodegenerative conditions that includes Parkinson’s disease, Lewy body dementia (DLB), and multiple system atrophy (MSA).

Multiple large prospective studies have found that approximately 80–90% of adults with isolated RBD (RBD without an already-known neurological condition) will eventually receive a diagnosis of Parkinson’s disease, DLB, or MSA over 10–14 years of follow-up. The average time from RBD onset to the overt neurological diagnosis is approximately 7–14 years — which is both alarming and a genuine opportunity window for research and preparation.

The biological explanation: all three conditions share a common thread — abnormal accumulation of misfolded alpha-synuclein protein in brain cells. This process typically begins in the brainstem, affecting the neurons that maintain REM muscle paralysis, before spreading to regions that produce the motor or cognitive symptoms recognized clinically. RBD emerges early in this process, years before overt neurological disease.

There is currently no proven treatment that slows or prevents the underlying neurological process in RBD. The immediate treatment goal is preventing injury.

Environmental safety — the most important first step:

• Remove hard, sharp, or heavy objects from arm’s reach of the bed (nightstands with sharp corners, lamps, picture frames)
• Pad the floor beside the bed (a thick yoga mat or folded comforters)
• Consider placing the mattress directly on the floor during an active phase
• For couples where the bed partner is at risk of injury, sleeping in separate beds may be the safest and most practical solution, at least temporarily during active phases
• Foam padding on bedframe rails and bedside furniture edges

Medications that reduce enactment frequency:

• Clonazepam 0.25–1 mg at bedtime: The most commonly used pharmacological treatment. Works by increasing inhibitory tone during REM sleep. Reduces enactment frequency and severity in most patients. Main concerns: next-day sedation, fall risk in older adults (this must be weighed against the injury risk from untreated RBD), and potential for dependence. Not appropriate for people with untreated sleep apnea due to respiratory suppression risk.
• Melatonin 3–15 mg at bedtime: Widely used, especially in older adults, people with cognitive concerns, or those with coexisting sleep apnea where clonazepam is a concern. May restore some REM atonia. Fewer side effects, no dependence risk, generally well-tolerated. Often preferred as the initial approach when falls risk or cognitive concerns are present.
• Medication cautions: SSRIs, SNRIs, tricyclic antidepressants, mirtazapine, and tramadol can precipitate or worsen RBD by suppressing REM muscle paralysis. If an antidepressant is clinically necessary, discuss the RBD association with your prescriber and choose the agent and dose with this in mind.

While no proven neuroprotective treatment currently exists, the years between RBD diagnosis and eventual neurological diagnosis is exactly the window that researchers worldwide are targeting with clinical trials. Several things are reasonable to discuss with your neurologist:

• Prodromal Parkinson’s research registries: Programs such as the PPMI (Parkinson’s Progression Markers Initiative, run by the Michael J. Fox Foundation) and similar international initiatives are actively enrolling people with isolated RBD and other prodromal markers to identify biomarkers and test interventions. Participation in research is one of the most meaningful options available to someone in this window. Ask your neurologist about current enrollment opportunities.
• Biomarker testing: Skin biopsy detection of phosphorylated alpha-synuclein (assays such as Syn-One or SYNTap) and CSF/plasma alpha-synuclein seed amplification assays can confirm synucleinopathy pathology in the prodromal phase. These are primarily research tools currently but are moving toward clinical availability.
• Additional prodromal markers to monitor: Hyposmia (reduced sense of smell), constipation, orthostatic hypotension (dizziness on standing), and subtle tremor or rigidity are additional prodromal markers that a neurologist should assess at annual follow-up.
• Lifestyle factors: Regular aerobic exercise has the strongest evidence among modifiable factors for supporting brain health in populations at elevated risk for Parkinson’s disease. Avoiding exposure to trichloroethylene (an industrial solvent with a well-documented epidemiological link to Parkinson’s disease) and certain pesticides is prudent where feasible.

• Dual orexin receptor antagonists (DORAs) — suvorexant, lemborexant, daridorexant. Block the brain’s wake-promoting orexin signaling. A newer class generally regarded as having a favorable benefit-risk balance. Can cause next-day drowsiness.
• Z-drugs — zolpidem, eszopiclone, zaleplon. Act on the same receptor system as benzodiazepines. Effective for short-term use. Carry an FDA boxed warning for complex sleep behaviors (sleep-driving, sleep-eating). Also next-day impairment, falls (especially in older adults), and potential for dependence. The FDA reduced the recommended starting dose for women in 2013 (to 5 mg for immediate-release and 6.25 mg for extended-release zolpidem) due to evidence that women metabolize the drug more slowly and are at greater risk of next-morning impairment; lower doses should also be considered for men.
• Benzodiazepines — e.g., temazepam. Older sedative-hypnotics. Generally not preferred for chronic insomnia due to tolerance, dependence, withdrawal, daytime sedation, cognitive effects, and falls.
• Low-dose doxepin — a sedating antidepressant used at low doses specifically for sleep-maintenance insomnia. Relatively well tolerated.
• Ramelteon — a melatonin-receptor agonist; can help with falling asleep. Generally low risk of dependence; modest effect size.
• Off-label sedating antidepressants — trazodone and mirtazapine are widely prescribed off-label for sleep. Evidence for insomnia without depression is limited. Mirtazapine can worsen restless legs and is associated with weight gain.

When a hypnotic is prescribed, the safest approach builds in an exit strategy from the start:

• Agree on the purpose and duration up front — typically short-term.
• Pair it with CBT-I so the behavioral skills allow eventual tapering.
• Taper gradually, not abruptly. A common approach is about a 25% dose reduction every one to two weeks, adjusted to your response.
• Never stop benzodiazepines, Z-drugs, opioids, antidepressants, or dopamine agonists suddenly on your own — significant withdrawal or rebound symptoms can occur.

Melatonin is a hormone the body produces as a darkness signal. As a supplement, it is best understood as a body-clock signal, not a sedative. Its clearest uses are circadian — easing jet lag and helping shift a delayed sleep phase — where small, correctly timed doses are what matter. For chronic insomnia it is at best a modest aid and is not a substitute for CBT-I.

Timing matters more than dose for circadian uses (best guided by a clinician). Because melatonin is sold as a supplement, product quality and actual content vary — choose a reputable, independently tested brand. Discuss melatonin use in children, pregnancy, and alongside other medications with a clinician.

• PAP machines (CPAP, APAP, BiPAP) — first-line for obstructive sleep apnea.
• Oral appliances — dental devices for OSA; an established alternative to PAP for appropriate patients.
• Hypoglossal nerve stimulators — an implanted option for selected PAP-intolerant OSA patients.
• Peroneal nerve stimulation devices — a non-drug option for restless legs.
• Light boxes — used in timed light therapy for circadian rhythm disorders.

• Diagnostic uncertainty: the picture does not fit cleanly, or several sleep problems overlap.
• Suspected complex or higher-risk OSA: significant heart or lung disease, or a negative home test despite strong clinical suspicion.
• Suspected narcolepsy or central hypersomnia: requires specialized testing and specialist management.
• Suspected REM sleep behavior disorder: needs in-lab study and neurological evaluation.
• Treatment failure: insomnia not responding to a proper course of CBT-I, RLS not controlled, or persistent sleepiness despite well-documented PAP use.
• RLS augmentation: transitioning off dopaminergic medication is best done with experienced guidance.
• PAP intolerance: ongoing inability to tolerate therapy despite troubleshooting.

Two markers of quality are worth seeking:

• For sleep centers: accreditation by the AASM, which maintains a public directory at sleepeducation.org.
• For CBT-I: the Society of Behavioral Sleep Medicine maintains a provider directory. Telehealth CBT-I is widely available and effective. Where trained providers are unavailable, an evidence-based digital CBT-I program is a reasonable bridge.

Coming prepared shortens the path: bring a completed sleep diary (at least one to two weeks), questionnaire scores, a full medication list, bed partner observations, and a short written list of your main questions.

The most important single habit is regular timing, anchored by a consistent wake-up time seven days a week. The wake time, more than the bedtime, sets the body clock and shapes the next night’s sleep drive. Large day-to-day swings keep the clock perpetually unsettled. Aim for a wake time you can keep every day, and let bedtime follow naturally from genuine sleepiness.

Light is the body clock’s master signal:

• Morning: Get bright light, ideally daylight, soon after waking. It strengthens the clock’s day signal and supports alertness.
• Evening: Dim lights in the hour or two before bed. Bright light late, including screens held close to the face, suppresses melatonin.
• Night: Keep the bedroom genuinely dark. Blackout curtains or an eye mask are inexpensive and effective.

Caffeine: Its effects persist for many hours. Stop caffeine at least eight hours before bedtime, and earlier if you are caffeine-sensitive. Account for hidden sources: tea, chocolate, some medications.

Alcohol: Widely used as a sleep aid and a poor one. It can shorten the time to fall asleep but fragments sleep in the second half of the night, suppresses REM, worsens snoring and apnea, and aggravates restless legs. Reducing or eliminating evening alcohol is one of the more reliably beneficial changes.

Exercise: Regular physical activity improves sleep quality and depth. For most people, moderate evening exercise is fine. Vigorous, intense exercise very close to bedtime disrupts sleep for some people and can aggravate RLS.

Bedroom environment: Cool (many people sleep best around the mid-60s Fahrenheit), dark, and quiet. A supportive mattress and pillow matter. Keep the bed associated with sleep — work, screens, and worry are better kept out of bed.

Naps: Not forbidden, but they cut both ways. A short nap (about 20 minutes) early in the afternoon can restore alertness, but napping spends the sleep drive needed for the coming night. For people with insomnia, naps are usually limited during treatment. For people with narcolepsy, scheduled naps are therapeutic.

Wind-down routine: Give yourself 30 to 60 minutes of low-stimulation, relaxing activity in dim light before bed. If a worried mind is the problem, set aside a “worry time” earlier in the evening. And avoid clock-watching during the night — checking the time fuels arithmetic and anxiety. Turn the clock away.

Week 1 — Baseline and stabilize:

• Keep your sleep diary every morning.
• Set one fixed wake-up time, seven days a week.
• Begin stimulus-control rules: bed for sleep and sex only; if awake and frustrated for ~20 minutes, get up.
• Stop or strictly limit daytime napping.
• Do not yet attempt sleep restriction — the first week is for baseline data.

Weeks 2–3 — Consolidate sleep:

• With your provider, set a time-in-bed window matched to actual sleep time (sleep restriction).
• Expect some daytime sleepiness — this is temporary and the mechanism working.
• Begin cognitive work: notice catastrophic thoughts about sleep and examine them.
• Begin practicing a relaxation skill during the day.

Weeks 4–6 and beyond — Titrate and reinforce:

• As sleep efficiency rises (consistently ~85–90%+), gradually extend time in bed.
• Re-score the ISI every couple of weeks to track progress.
• Hold the fixed wake time and stimulus-control habits even as sleep improves.

• “It got worse before it got better.” Common and expected with sleep restriction. Stay the course — this is sleep drive building, not failure.
• “I plateaued.” Re-check the basics: is the wake time truly fixed? Are you actually getting out of bed when awake? Has napping or caffeine crept back? A plateau is usually a drifted habit.
• “My sleep is fine some nights and terrible others.” Variable nights are normal. Judge progress by the trend across two weeks, not single nights.
• “I did everything and it still isn’t working.” Reconsider the diagnosis. Untreated sleep apnea, restless legs, or a circadian disorder underneath the insomnia is the most common reason good CBT-I underperforms.

• Avoid known triggers through the day — caffeine, alcohol, nicotine.
• Take iron, if prescribed, correctly: with vitamin C, away from food, coffee, tea, and calcium.
• Fit in moderate exercise earlier in the day rather than intensely late at night.
• In the evening, use counterstimulation as needed — walking, stretching, leg massage, warm or cool applications.
• When symptoms strike during enforced rest, engage your mind with something absorbing.
• Take any RLS medication on schedule, and watch for early signs of augmentation.

• Wear the mask for short periods while awake in the first days to build familiarity.
• Make sure comfort features are on: the ramp (gradual pressure build-up) and heated humidification.
• Aim to use it every night, even if early on you manage only part of the night. Consistency builds the habit.
• If the mask leaks, hurts, or does not suit you, contact your equipment supplier for a different type or size. Do not endure a bad mask.
• Review your machine’s data (usage hours, residual AHI, leak) with your clinician at early follow-up.
• Note that insurers often require documented use in the first few months for continued coverage.

• Depression and anxiety: The relationship with insomnia is genuinely two-way. The modern approach is to treat both rather than waiting for one to fix the other. CBT-I can itself improve depressive and anxiety symptoms.
• Chronic pain: Pain disrupts sleep and poor sleep lowers pain tolerance. Some pain medications (particularly opioids) can disturb breathing during sleep.
• Diabetes and metabolic disease: Sleep loss and untreated apnea worsen insulin resistance. Screening people with type 2 diabetes for sleep apnea is reasonable.
• Cardiovascular disease: Untreated OSA is closely tied to hypertension, atrial fibrillation, heart failure, and stroke. Anyone with hard-to-control blood pressure deserves a low threshold for OSA screening.
• Neurological conditions: Parkinson disease frequently involves disrupted sleep, RLS, and REM sleep behavior disorder.
• Reflux, asthma, and COPD can all fragment sleep and interact with sleep-disordered breathing.

Sleep changes substantially in pregnancy. Restless legs is common and often relates to iron, so iron status deserves particular attention. Insomnia is also common, and because medication options are limited, behavioral treatment (adapted CBT-I) is preferred. Sleep-disordered breathing can emerge or worsen, especially later in pregnancy. All sleep treatment in pregnancy should be coordinated with the obstetric team.

Sleep architecture naturally changes with age — lighter sleep, more awakenings, and a tendency toward an earlier body clock. Some of this is normal aging. But older adults also carry more conditions that genuinely disrupt sleep. Two cautions: sedating medications (benzodiazepines, Z-drugs, OTC antihistamines) carry heightened risk of falls, confusion, and cognitive effects. CBT-I is effective and safe in older adults and is the preferred insomnia treatment.

Behavioral strategies and consistent routines are the foundation for young people. Pediatric OSA — often from enlarged tonsils and adenoids — is important to identify because treatment is frequently curative. In adolescents, a delayed body clock is biologically common, which is part of why early school start times collide with teenage physiology. Restless legs occurs in children too, and iron status is relevant. Sleep concerns in children and teens should be evaluated by a pediatric clinician.

A medication review is part of every sleep evaluation because a meaningful share of sleep complaints are caused or worsened by something already prescribed. Common culprits include stimulating antidepressants, sedating antihistamines, beta-blockers, corticosteroids, decongestants, late-day diuretics, opioids, and alcohol. The action is never to stop a medication on your own — bring the full list to your clinician so timing or alternatives can be considered.

The epidemiological evidence linking habitual short sleep (fewer than 6 hours per night) to adverse health outcomes is consistent across many large populations:

• Cardiovascular disease: People who habitually sleep fewer than 6 hours per night have approximately 20–30% higher risk of heart attack and stroke in large population studies, after adjusting for other known risk factors.
• Type 2 diabetes: Short sleep is associated with increased insulin resistance, impaired glucose tolerance, and higher risk of developing type 2 diabetes. Even a few nights of sleep restriction in controlled experiments significantly reduces insulin sensitivity in healthy adults.
• Obesity: Sleep deprivation increases ghrelin (the hunger hormone) and decreases leptin (the satiety hormone), promoting overeating and preference for high-calorie foods. Short sleep duration is one of the most consistently identified modifiable risk factors for obesity in large longitudinal studies.
• Immune function: Sleep deprivation impairs immune response, including antibody production after vaccination and resistance to respiratory viral infections.

OSA and hypertension: OSA is widely recognized as the most common identifiable cause of drug-resistant hypertension. Repeated oxygen desaturations and arousals during sleep activate the sympathetic nervous system, raise catecholamine and cortisol levels, and produce nocturnal blood pressure surges. CPAP treatment of OSA modestly reduces 24-hour blood pressure by approximately 2–3 mmHg systolic in most trials. The effect is larger in people with higher CPAP adherence, more severe OSA, and nocturnal hypertension patterns.

The SAVE trial and its limitations: A major randomized trial (SAVE, 2016) found that PAP therapy did not significantly reduce serious cardiovascular events (heart attack, stroke) in adults with moderate-to-severe OSA and established cardiovascular disease. However, average CPAP use in the trial was only about 3.3 hours per night — well below the threshold for meaningful benefit. A separate trial (ISAACC) reached similar neutral conclusions with similar adherence limitations. Whether adequately adherent CPAP therapy prevents hard cardiovascular events remains an open question awaiting better-designed trials.

Current clinical guidance: CPAP is still recommended for symptomatic OSA, with strong emphasis on achieving adherence above 4 hours per night. Symptomatic improvement, blood pressure reduction, and quality-of-life benefits are well-supported even if prevention of major cardiovascular events is not yet proven in high-adherence trials.

Atrial fibrillation (AF): OSA increases the risk of developing AF by approximately 2–4 fold and substantially increases AF recurrence after cardioversion and catheter ablation. Many electrophysiologists now routinely screen AF patients for OSA and recommend CPAP as part of rhythm management, given observational data showing substantially reduced AF recurrence rates with adequate CPAP use.

Heart failure: OSA is present in 30–50% of patients with heart failure. In heart failure with reduced ejection fraction (HFrEF), central sleep apnea and Cheyne-Stokes respiration are also common. ASV therapy is contraindicated in HFrEF — this is a critical safety point detailed in the Central Sleep Apnea section. Optimizing heart failure medications is the primary treatment approach for CSA in HFrEF patients.

Type 2 diabetes: CPAP modestly improves insulin sensitivity and glucose control in people with both OSA and type 2 diabetes, with average HbA1c reductions of 0.2–0.4% in trials. CPAP is not a standalone diabetes treatment, but treating OSA is part of optimizing overall metabolic health in people with both conditions.

Stroke: OSA is present in 60–70% of acute stroke patients and is an independent risk factor for stroke. Early CPAP initiation after stroke may support neurological recovery in observational studies, though adherence in this population is particularly challenging and requires extra support.

OSA and excess body weight drive each other in a reinforcing cycle:

• Excess weight deposits fat around the upper airway, narrowing the passage and increasing OSA risk and severity
• OSA fragments sleep, elevates cortisol, impairs growth hormone secretion (which normally occurs during deep sleep), and worsens the hormonal environment for weight regulation
• Disrupted sleep promotes hunger and caloric intake, making weight maintenance harder

Breaking this cycle requires addressing both simultaneously — not waiting for weight loss before starting CPAP, and not assuming CPAP alone will facilitate weight loss.

The weight-AHI relationship: On average, every 10% reduction in body weight produces approximately 26% improvement in AHI. This is a powerful lever: significant weight loss (25–30% of body weight or more) can resolve or substantially reduce OSA in some patients. CPAP should be maintained during the weight loss process and re-evaluated with a new study afterward.

GLP-1/GIP receptor agonists: Tirzepatide (Zepbound) is now FDA-approved specifically for moderate-to-severe OSA in adults with obesity (December 20, 2024). In the SURMOUNT-OSA Phase 3 trials, tirzepatide reduced AHI by up to 62% alongside significant weight loss — the first pharmacological treatment targeting OSA at a root cause. It is intended to be used alongside PAP therapy, not as a replacement.

Memory of sleep is unreliable. Every few months, and any time things feel like they are slipping, repeat the objective measures:

• Insomnia: Re-score the ISI and keep a one-week sleep diary. A rising score is an early signal to act.
• Daytime sleepiness: Re-score the ESS. Creeping sleepiness on PAP therapy is a prompt to check the device and fit.
• Restless legs: Re-score the IRLS and note whether symptoms are starting earlier in the day or spreading.
• PAP data: Review usage hours, residual AHI, and mask leak.

Insomnia: CBT-I tends to last, but maintenance matters. Keep a consistent wake time, protect the bed-equals-sleep association, and resist the urge to catch up with long lie-ins. When bad nights cluster, return to the core techniques: tighten time in bed, hold the wake time, use stimulus control.

Restless legs: Recheck iron studies periodically. Stay alert for augmentation. Report any new medication to the clinician managing your RLS.

Sleep apnea: PAP works only while used, so maintenance is about comfort and equipment. Annual follow-up is reasonable. Replace masks and supplies regularly. Significant weight change can alter pressure needs.

The maintenance mindset: Maintenance is not a sign that treatment was fragile — it is normal management of chronic conditions. The effort required to keep gains is far smaller than the effort it took to win them.

What to watch for and note: Loud or habitual snoring, pauses in breathing followed by gasping, restlessness or repetitive leg kicking, talking or shouting, acting out dreams, and the rough timing of sleep and wakefulness.

How to capture it: Brief written notes are valuable; a short phone audio or video clip, recorded with consent, can be even more helpful.

What helps beyond observing:

• Supporting a consistent schedule.
• Not arguing about sleep at 2 a.m.
• Avoiding shaming language about snoring or PAP equipment.
• Helping troubleshoot a PAP mask.
• If there is dream-enactment behavior, helping make the bedroom safer until it is evaluated.

1. Start a sleep diary today. Two weeks of simple records is the foundation for every conversation and decision that follows.
2. Screen yourself for sleep apnea. Answer the STOP-BANG questions honestly. If snoring, witnessed pauses, and daytime sleepiness are present, make OSA evaluation your top medical priority.
3. Address safety first. If you are falling asleep while driving, treat that as urgent now — do not wait.
4. Get an accurate diagnosis before committing to a treatment. Treating the wrong target wastes the most precious resource: time.
5. If insomnia is the problem, pursue CBT-I. Begin behavioral steps now and arrange access to a provider or digital program.
6. If restless legs is the problem, get iron studies and review your medications. Iron repletion when stores are low is one of the most effective and underused steps in sleep medicine.
7. Claim the free wins. Lock in a consistent wake time, get morning light, move caffeine earlier, separate alcohol from bedtime, protect a wind-down period.
8. Book the appointment and come prepared. Bring the diary, the scores, the medication list, bed partner observations, and your questions.

• Based on my sleep diary and symptoms, what do you think is the most likely cause?
• Could a breathing problem (sleep apnea) be involved, and should I be screened?
• Are any of my current medications or supplements affecting my sleep?
• Should I have bloodwork — for example, iron studies or thyroid function?
• Do you recommend a home sleep apnea test, an in-lab sleep study, or neither?
• Is this something you will manage, or should I see a sleep specialist?

• Do my symptoms meet the criteria for restless legs syndrome?
• What are my ferritin level and transferrin saturation, and do they indicate treatment with iron?
• If iron is recommended, should it be oral or intravenous, and when will we recheck?
• Which of my medications could be worsening this, and are there alternatives?
• If a medication for RLS is needed, why this one — and what is its risk of augmentation?
• What symptoms of augmentation should make me call you?

• Is CBT-I appropriate for me, and how do I access it?
• If a trained provider is hard to find, is a digital CBT-I program a reasonable option?
• If we consider a sleep medication, is it short-term or ongoing, what are the risks, and what is the plan to stop it?
• How will we measure whether treatment is working?
• Could an underlying issue — mood, pain, another sleep disorder — be driving this?

Before the study:

• Is this a home test or in-lab study, and why?
• How should I prepare — medications, caffeine, what to bring?
• When and how will I get the results?
• What is my expected out-of-pocket cost?

When OSA is diagnosed:

• How severe is my apnea, and what does that mean for my health?
• What are my treatment options — PAP, oral appliance, positional measures, weight management, surgery — and which do you recommend?
• If PAP is recommended, who will help me with mask fit and the first few weeks?
• What usage data will be tracked, and what does my insurance require?
• When will we recheck how well treatment is working?

• Does my re-measured score (ISI, ESS, IRLS, or PAP data) show I am responding?
• If I am not improving as expected, what is the next step — a different treatment, or referral?
• How long should I stay on this treatment, and what does maintenance look like?
• What should prompt me to contact you sooner rather than waiting?
• Is there anything in my overall health — blood pressure, mood, weight, glucose — that my sleep treatment is helping or that we should watch?

• Week 1–2: Measuring phase — sleep diary and questionnaires; claim the “free wins” of consistent schedule, light, caffeine, and alcohol timing. Behavioral changes begin; do not expect a cure yet.
• Week 2–4: Evaluation and diagnosis; first-line treatment begins. CBT-I started; PAP therapy initiated; iron repletion started for RLS.
• Week 4–8: CBT-I produces meaningful gains. PAP benefit builds with consistent use. RLS medication adjusted to effect.
• Month 2–3: Iron repletion shows its effect on RLS. Circadian treatments take hold with consistent light and melatonin timing. Re-measure and confirm response.
• Ongoing: Maintain the consistent schedule, re-measure periodically, replace PAP supplies, recheck iron, watch for RLS augmentation, and keep a written relapse plan.

• Drowsy driving. Falling asleep or fighting to stay awake at the wheel — stop driving while sleepy and seek evaluation now.
• Witnessed apneas. A bed partner sees you stop breathing, gasp, or choke — pursue OSA evaluation promptly.
• Sleep attacks or cataplexy. Irrepressible daytime sleep or sudden muscle weakness with emotion — seek specialist evaluation.
• Dream enactment. Acting out dreams with risk of injury — make the environment safe and seek neurological evaluation.
• Restless legs that is new, rapidly worsening, or one-sided. Warrants medical assessment.
• RLS augmentation. Symptoms creeping earlier, intensifying, or spreading on medication — contact your clinician; do not increase the dose.
• Mood collapse or thoughts of self-harm. Seek help promptly; in the U.S., call or text 988.
• Treatment not working. A proper course of first-line treatment without improvement is a trigger for re-evaluation or referral — not for giving up.

• American Academy of Sleep Medicine (AASM): The U.S. professional body for sleep medicine. Its public site (sleepeducation.org) includes a directory of AASM-accredited sleep centers.
• Society of Behavioral Sleep Medicine: Maintains a directory of providers trained in behavioral sleep medicine — useful for finding a CBT-I therapist.
• RLS Foundation: Patient education and clinician-directory resources for restless legs syndrome.
• Narcolepsy Network and Wake Up Narcolepsy: Education and support for narcolepsy and related conditions.
• Sleep Foundation: Consumer education. Use with a caveat: consumer sites vary in quality and some carry commercial content.

Because trained CBT-I providers are unevenly distributed, digital options matter. Several evidence-based digital programs have been studied in clinical trials. Telehealth CBT-I delivered by a trained provider is also well supported. The free CBT-I Coach app (developed for veterans’ health services) is best used alongside a provider. Ask your clinician what is available and credible in your region. The goal is a structured, evidence-based program that delivers the actual components — stimulus control, sleep restriction, and cognitive work — rather than a generic “sleep tips” app.

• Insurance generally covers diagnostic sleep testing and PAP therapy when criteria are met, but coverage comes with documentation rules.
• PAP coverage is typically conditional on demonstrated use during an initial period, with data pulled from the machine.
• Home sleep testing is often required before an in-lab study unless specific factors justify going straight to the lab.
• If cost or access is a barrier, say so plainly to your clinician — there are often lower-cost testing pathways, and CBT-I has free and low-cost digital options.
• Persistence is reasonable. Sleep disorders are medical conditions, and effective treatment is worth pursuing.

• Treating a symptom without finding the cause — reaching for a sleep aid without asking whether the real problem is apnea, restless legs, or a circadian mismatch.
• Spending more time in bed to get more sleep — the intuitive response, and usually the wrong one.
• Using alcohol as a sleep aid.
• Judging a night by the clock — watching the time feeds anxiety.
• Giving up on CBT-I in the first week.
• Escalating the dose of an RLS dopamine agonist when symptoms worsen — if the worsening is augmentation, more medication makes it worse.
• Abandoning PAP after a rough first week — most early problems are fixable.
• Ignoring iron in restless legs.
• Treating daytime sleepiness as a character flaw — it is a medical symptom.
• Chasing sleep with technology and supplements before fixing fundamentals.
• Stopping treatment the moment things improve — maintenance is normal management.

• CBT-I: NICE (UK) and European Sleep Research Society (ESRS) guidelines both recommend CBT-I as the first-line treatment for chronic insomnia, consistent with U.S. guidelines. Access to trained CBT-I therapists varies significantly by country.
• Dual orexin receptor antagonists (DORAs): Daridorexant (Quviviq) is approved by the EMA for insomnia in adults. Suvorexant is not marketed in most European countries. Lemborexant received EMA approval in 2024.
• Z-drugs and benzodiazepines: NICE recommends short-term use only (2–4 weeks) and explicitly discourages long-term prescribing. Several European countries have implemented prescribing restrictions and deprescribing programs.
• Melatonin: Prolonged-release melatonin (Circadin) is approved by the EMA for insomnia in patients aged 55 and over — a more specific indication than the U.S. approach, where melatonin is sold as an unregulated dietary supplement.
• Sodium oxybate (Xyrem): EMA-approved for narcolepsy with cataplexy; access and reimbursement vary by country, with some nations requiring prior authorization through specialist centres.
• Pitolisant (Wakix): EMA-approved for narcolepsy (both excessive daytime sleepiness and cataplexy). Pitolisant was originally developed and first approved in Europe before the U.S.
• CPAP and oral appliances: Widely available across Europe. In the UK, the NHS provides CPAP equipment and follow-up at no cost to the patient after diagnosis through an NHS sleep service.
• Hypoglossal nerve stimulation (Inspire): CE-marked and available in several European countries, including Germany, the Netherlands, and Belgium. Reimbursement policies vary.

• Suvorexant (Belsomra): Japan was the first country to approve suvorexant (2014) and has extensive post-marketing experience with this DORA.
• Lemborexant (Dayvigo): Approved by PMDA and widely used for insomnia in Japan.
• Ramelteon (Rozerem): A melatonin receptor agonist approved and commonly prescribed in Japan for insomnia with difficulty falling asleep. Also approved in the U.S. but used less frequently there.
• Sodium oxybate: Available for narcolepsy with cataplexy through specialist centres.
• Cultural context: Japanese sleep medicine recognizes inemuri (sleeping in public settings) as culturally normative and incorporates cultural considerations into diagnostic evaluation of excessive daytime sleepiness and sleep duration norms.

• CBT-I: Canadian guidelines (Canadian Sleep Society) recommend CBT-I as first-line for chronic insomnia, consistent with international consensus. Access varies by province and is generally better in urban centres.
• DORAs: Lemborexant received Health Canada approval. Daridorexant is also approved. Provincial formulary coverage varies.
• CPAP: Provincial health insurance programs cover CPAP equipment to varying degrees. Some provinces (e.g., Ontario through the Assistive Devices Program) provide partial funding; others require private insurance or out-of-pocket payment.
• Sodium oxybate: Approved for narcolepsy with cataplexy. Dispensed through specialized distribution programs.
• Pitolisant: Approved by Health Canada for narcolepsy.

• CBT-I: Recommended as first-line by the Australasian Sleep Association. Access is expanding through digital CBT-I programs covered by some private health insurers.
• Suvorexant: TGA-approved and available in Australia for insomnia. Listed on the Pharmaceutical Benefits Scheme (PBS) with appropriate authority prescribing.
• Melatonin: Prescription-only in Australia (unlike the U.S. where it is an over-the-counter supplement). This provides tighter quality control but requires a doctor visit.
• CPAP: Available through the public hospital system and private providers. The National Disability Insurance Scheme (NDIS) may fund CPAP equipment for eligible participants.
• Sodium oxybate: Available under the Special Access Scheme for narcolepsy with cataplexy.

• Melatonin regulation: Over-the-counter in the U.S. and Canada; prescription-only in the EU, UK, Japan, and Australia. Quality and dosing consistency are generally better in regulated markets.
• Benzodiazepine prescribing: The EU, UK, and Australia have implemented stricter prescribing limits and deprescribing guidance for benzodiazepine and Z-drug hypnotics than the U.S., where long-term prescribing remains more common.
• Drug availability: Some medications approved in one region may not be available in another. Patients relocating internationally should discuss equivalent treatment options with a sleep specialist in their new country before moving.
• Diagnostic thresholds: The ICSD-3 classification is used internationally, but some countries and insurers use different AHI thresholds or symptom criteria to determine treatment eligibility for sleep apnea.

• These behaviors can occur after the very first dose, even at the lowest recommended dose, with or without alcohol or other sedatives.
• Contraindication: Z-drugs must NOT be prescribed to anyone who has had a complex sleep behavior on any Z-drug. If you experience a complex sleep behavior, stop the medication immediately and contact your doctor.
• Gender dosing: Since 2013, the FDA has required lower recommended starting doses for women (zolpidem: 5 mg for immediate-release, 6.25 mg for extended-release) because women metabolize zolpidem more slowly, leading to higher next-morning blood levels and impaired driving ability.
• This warning does NOT apply to DORAs (suvorexant, lemborexant, daridorexant) — which have a different mechanism and have not been associated with the same complex sleep behavior risk.

REMS Program (Risk Evaluation and Mitigation Strategy): All sodium oxybate products are available only through tightly controlled FDA REMS programs. Xyrem and Xywav (Jazz Pharmaceuticals) are dispensed through the XYWAV and XYREM REMS; Lumryz (Avadel) is dispensed through the separate LUMRYZ REMS. Despite having separate program names, all three products share the same core safety requirements:

• Restricted distribution: Sodium oxybate is dispensed exclusively through a single certified specialty pharmacy. It cannot be filled at your local retail pharmacy.
• Prescriber certification: Only certified prescribers who have completed a REMS training program can prescribe sodium oxybate.
• Patient enrollment: Every patient must enroll in the REMS program and acknowledge understanding of the risks — including the alcohol/CNS depressant contraindication — before the medication can be dispensed.
• Schedule III controlled substance: Sodium oxybate (GHB) is tightly scheduled due to its abuse potential. It cannot be picked up in person; it is only mailed from the certified pharmacy.

Practical note for patients: Expect the first prescription to take 7–14 days to process through the REMS enrollment steps. Your doctor will coordinate this. Never take sodium oxybate with any alcohol or sedative — even a small amount of alcohol can be life-threatening when combined with this medication.

Sleep medications interact with many commonly prescribed drugs. The interactions below are the most clinically significant — some are dangerous enough that combination should be avoided or requires close monitoring.

Important: This table covers the most clinically significant interactions. Always inform every doctor, pharmacist, and healthcare provider of all medications you take — including over-the-counter products, supplements, and herbal remedies — before starting or changing any sleep medication.

Sleep disorders are common in pregnancy. The general principle is behavioral approaches first — CBT-I for insomnia, iron supplementation for RLS, and CPAP for sleep apnea remain safe and effective. Most sleep medications have limited or concerning human pregnancy data and should be used only when benefits clearly outweigh risks, in consultation with both your sleep specialist and obstetric team.

Always coordinate sleep medication decisions in pregnancy with your obstetric team. Many narcolepsy patients continue modafinil or sodium oxybate under specialist supervision when symptom severity warrants it — the decision is individualized.

• CBT-I for chronic insomnia is effective and durable. Multiple high-quality randomized trials confirm that CBT-I produces meaningful, lasting improvements in sleep onset, sleep maintenance, and sleep efficiency. It outperforms sleep medications long-term. This is one of the most robustly supported behavioral interventions in all of medicine.
• CPAP effectively controls OSA breathing events when worn. When used consistently, CPAP virtually eliminates apneas and hypopneas, normalizes blood oxygen, and improves daytime sleepiness in the large majority of users. The central unresolved question is not whether CPAP works but whether people wear it consistently enough.
• Untreated moderate-to-severe OSA impairs daytime function and driving safety. The impairment in sustained attention, reaction time, and driving performance is well-documented and is reversed by effective CPAP treatment. This is not controversial.
• Isolated RBD is a prodromal synucleinopathy marker. The 80–90% conversion rate from isolated RBD to Parkinson’s disease, Lewy body dementia, or multiple system atrophy over 10–14 years is one of the strongest predictive biomarker relationships in clinical neurology.
• Sodium oxybate is the most comprehensively effective treatment for narcolepsy type 1. It addresses excessive daytime sleepiness, cataplexy, and disrupted nocturnal sleep — three distinct problems — with a single medication. This breadth of efficacy is unusual and well-supported by multiple high-quality trials.
• ASV is contraindicated in heart failure with reduced ejection fraction. The SERVE-HF trial demonstrated increased mortality from ASV in patients with HFrEF and central sleep apnea. This is a settled safety finding with direct clinical consequences.

• Does CPAP prevent cardiovascular events? The most consequential open question in sleep apnea research. The SAVE and ISAACC trials both found no significant reduction in cardiovascular events with CPAP in patients with established cardiovascular disease — but both had low average adherence (approximately 3.3 hours per night). Whether adequately adherent CPAP therapy prevents heart attacks and strokes in OSA patients remains unproven in a properly designed, high-adherence trial.
• Does treating asymptomatic mild OSA change long-term outcomes? Many people have an AHI of 5–14 events per hour with no meaningful daytime symptoms. Whether treating this reduces cardiovascular risk, cognitive decline, or other long-term harms is unknown. Current practice is to individualize based on comorbidities and risk factors rather than treat everyone with any detectable OSA.
• What is the optimal first-line therapy for mild-to-moderate OSA? CPAP, oral appliances, positional therapy, hypoglossal nerve stimulation, and weight management all reduce AHI in mild-to-moderate OSA. No large randomized trial has definitively compared them on patient-centered long-term outcomes. The choice is currently individualized based on anatomy, lifestyle, preferences, and adherence likelihood.
• Can neuroprotection prevent synucleinopathy in RBD patients? Multiple clinical trials are actively testing whether interventions can delay or prevent Parkinson’s disease in people with prodromal markers including isolated RBD. No proven preventive treatment currently exists. This is one of the most actively researched frontiers in neurology, with results expected from several ongoing trials in the coming years.
• Should CBT-I be combined with medication or sequenced first? Most guidelines recommend CBT-I first with medication as a later option. For severe insomnia, combination approaches may produce faster early improvement while building the behavioral foundation for lasting change. The optimal sequencing strategy has not been tested in large randomized trials.
• Do digital CBT-I programs work as well as therapist-delivered CBT-I? Digital programs have good evidence for moderate insomnia and are far more accessible. Whether they match the outcomes of face-to-face CBT-I for all patients — especially those with complex or treatment-resistant insomnia — remains an active research question.

Sleep medicine research is moving quickly, particularly in narcolepsy (orexin replacement therapies approaching FDA approval), OSA pharmacotherapy (tirzepatide and new molecular approaches), and neuroprotection in prodromal synucleinopathy. The best places for patients to follow developments:

• ClinicalTrials.gov — the official U.S. registry of clinical trials; search your condition to find actively enrolling studies. For people with RBD especially, this is worth checking regularly.
• AASM SleepEducation.org — patient-facing summaries of guideline updates and research from the American Academy of Sleep Medicine
• Narcolepsy Network (narcolepsynetwork.org) — patient organization with research updates and community support for narcolepsy and idiopathic hypersomnia
• Michael J. Fox Foundation PPMI (michaeljfox.org) — the premier prodromal Parkinson’s research registry, actively enrolling people with RBD and other prodromal markers
• Restless Legs Syndrome Foundation (rls.org) — research updates, support resources, and provider directories for RLS/Willis-Ekbom disease

• Actigraphy: A wrist-worn device that estimates sleep and wake from movement over days or weeks; useful for circadian patterns and cross-checking a sleep diary.
• AHI (apnea-hypopnea index): The average number of breathing pauses and partial obstructions per hour of sleep; the main number used to grade OSA severity.
• APAP (auto-titrating positive airway pressure): A PAP device that automatically adjusts pressure breath by breath within a set range; often used as the default starting mode because it adapts to position, sleep stage, and airway changes overnight.
• Apnea: A pause in breathing during sleep lasting at least ten seconds.
• Augmentation: A worsening of restless legs syndrome caused by long-term treatment, most associated with dopamine-agonist medications: symptoms start earlier, become more intense, or spread to other body parts.
• BiPAP (bilevel positive airway pressure): A PAP device that delivers a higher pressure on inhalation and a lower pressure on exhalation; used when standard CPAP pressure is uncomfortable, when higher pressures are needed, or when central apneas or hypoventilation are present.
• CBT-I: Cognitive behavioral therapy for insomnia — a structured, short-term behavioral treatment and the recommended first-line treatment for chronic insomnia.
• Cataplexy: Sudden, brief muscle weakness triggered by strong emotion; a specific feature of narcolepsy type 1.
• Circadian rhythm: The roughly 24-hour internal body clock that governs the timing of sleep, alertness, hormones, and other functions.
• CPAP (continuous positive airway pressure): The standard PAP device; delivers a single fixed pressure throughout the night to hold the airway open. See also APAP, BiPAP.

• DORA (dual orexin receptor antagonist): A newer class of prescription sleep medication that dampens the brain’s wake-promoting orexin system.
• EDS (excessive daytime sleepiness): Difficulty staying awake or alert during the day; a symptom, not a diagnosis.
• Ferritin: A blood test reflecting the body’s iron stores; low or low-normal ferritin is important in restless legs syndrome.
• HSAT (home sleep apnea test): A simplified breathing study done at home to diagnose OSA.
• Hypopnea: A partial reduction in airflow during sleep, usually with a drop in blood oxygen or a brief arousal.
• Idiopathic hypersomnia: A chronic neurological disorder of excessive sleep need and profound difficulty waking, without the specific features of narcolepsy such as cataplexy or rapid-onset REM; diagnosed after other causes of sleepiness have been excluded.
• Insomnia: Persistent difficulty falling asleep, staying asleep, or waking too early, with adequate opportunity to sleep, plus daytime consequences.
• ISI (Insomnia Severity Index): A short questionnaire scoring insomnia severity, used to track change over time.

• Melatonin: A hormone produced by the pineal gland as darkness falls, signaling the body that nighttime has arrived; available as an over-the-counter supplement used mainly for circadian rhythm adjustment and jet lag rather than as a conventional sleeping pill.
• MSLT (multiple sleep latency test): A daytime test measuring how quickly a person falls asleep; used to diagnose narcolepsy.
• MWT (maintenance of wakefulness test): A daytime test of the ability to stay awake in a quiet setting; assesses treatment response and fitness for safety-critical tasks.
• Narcolepsy: A neurological disorder of sleep-wake regulation causing severe daytime sleepiness; type 1 also features cataplexy and is caused by loss of orexin-producing neurons.
• Orexin / hypocretin: A brain signaling chemical (neuropeptide) that promotes and stabilizes wakefulness; loss of orexin-producing neurons causes narcolepsy type 1. Dual orexin receptor antagonists (DORAs) are a newer class of sleep medication that blocks this wake signal; orexin receptor agonists are in development for narcolepsy.
• OSA (obstructive sleep apnea): Repeated collapse of the upper airway during sleep, causing breathing pauses, oxygen dips, and fragmented sleep.
• PAP / CPAP: Positive airway pressure therapy; a machine delivers pressurized air through a mask to hold the airway open. CPAP delivers a single continuous pressure. See also APAP, BiPAP.
• Parasomnias: A group of sleep disorders involving abnormal movements, behaviors, emotions, or perceptions during sleep or sleep-wake transitions; includes sleepwalking, sleep terrors, confusional arousals, sleep-related eating disorder, and REM sleep behavior disorder.
• PLMD (periodic limb movement disorder): A sleep disorder diagnosed when periodic limb movements during sleep (PLMS) are frequent enough to fragment sleep and cause daytime symptoms; distinguished from incidental PLMS, which are common and often clinically insignificant.
• PLMS (periodic limb movements of sleep): Repetitive limb movements during sleep, often seen with RLS; become clinically relevant when they fragment sleep sufficiently to cause symptoms (see PLMD).
• Polysomnography (PSG): A comprehensive in-lab sleep study recording brain waves, breathing, oxygen, heart rhythm, and movement.

• REM sleep: Rapid eye movement sleep — the stage with vivid dreaming; the body is normally held still.
• RBD (REM sleep behavior disorder): A disorder in which normal REM muscle paralysis is lost and the person acts out dreams; warrants neurological evaluation.
• RLS (restless legs syndrome): Also called Willis-Ekbom disease; an urge to move the legs with uncomfortable sensations, worse at rest and in the evening, relieved by movement.
• Sleep efficiency: The percentage of time in bed actually spent asleep; a central number in CBT-I.
• Sleep latency: The time it takes to fall asleep after lights out.
• Sleep restriction (sleep consolidation): A CBT-I technique that temporarily limits time in bed to match actual sleep, strengthening sleep drive.
• Stimulus control: A CBT-I technique that rebuilds the link between bed and sleep by restricting bed use to sleep and getting up when wakeful.
• STOP-BANG: A short screening questionnaire estimating the likelihood of obstructive sleep apnea.
• Transferrin saturation: A blood test reflecting iron available for the body to use; relevant to RLS treatment decisions.
• ASV (adaptive servo-ventilation): A PAP device mode that delivers variable pressure support adjusted breath by breath to stabilize irregular breathing. Used for central sleep apnea and treatment-emergent central apnea. Contraindicated in heart failure with reduced ejection fraction (EF ≤45%).
• COMISA: Comorbid insomnia and sleep apnea — a common and underrecognized coexistence of the two most prevalent sleep disorders. Treating only one typically produces incomplete results; concurrent CBT-I plus PAP therapy produces better outcomes than sequential treatment.
• TECA (treatment-emergent central apnea): Central apneas that appear or worsen after starting PAP therapy for obstructive OSA. Usually resolves spontaneously within 1–3 months; persistent cases may require ASV (after confirming normal cardiac ejection fraction).
• ODI (oxygen desaturation index): The number of times per hour that blood oxygen drops by 3% or 4% below baseline; a measure of the oxygen burden from sleep-disordered breathing, reported alongside or instead of AHI in some labs.
• NREM sleep: Non-rapid eye movement sleep — the deeper sleep stages (N1, N2, N3/slow-wave) that alternate with REM in 90-minute cycles. Slow-wave sleep (N3) is most concentrated in the first half of the night and is critical for physical restoration and memory consolidation.
• Sleep architecture: The pattern and proportion of sleep stages across the night. Normal adult sleep alternates through NREM and REM in approximately 90-minute cycles, with 4–6 cycles per night. Disrupted architecture is a common result of sleep disorders and some medications.
• SOREMP (sleep-onset REM period): The appearance of REM sleep within 15 minutes of falling asleep. Normally REM does not occur until 60–90 minutes into the sleep period. Two or more SOREMPs on an MSLT are a diagnostic criterion for narcolepsy.
• Synucleinopathy: A group of neurodegenerative diseases characterized by abnormal accumulation of misfolded alpha-synuclein protein in brain cells, including Parkinson’s disease, Lewy body dementia (DLB), and multiple system atrophy (MSA). Isolated RBD is a prodromal marker for all three.
• REM without atonia (RWA): The polysomnographic hallmark of RBD — the persistence of muscle activity on EMG during REM sleep that should normally be absent. The diagnostic criterion for RBD on PSG.
• Lemborexant (Dayvigo): A dual orexin receptor antagonist (DORA) FDA-approved for insomnia characterized by difficulty with sleep onset and/or sleep maintenance. Available in 5 mg and 10 mg strengths. Schedule IV controlled substance.
• Daridorexant (Quviviq): A dual orexin receptor antagonist (DORA) FDA-approved for insomnia. Available in 25 mg and 50 mg strengths. Schedule IV controlled substance. Approved by EMA in 2022.
• Pitolisant (Wakix): A histamine H3 receptor inverse agonist FDA-approved for excessive daytime sleepiness and cataplexy in narcolepsy. Non-scheduled (no DEA controlled-substance classification). Interacts with strong CYP2D6 inhibitors.
• Solriamfetol (Sunosi): A selective dopamine and norepinephrine reuptake inhibitor (DNRI) FDA-approved for excessive daytime sleepiness in narcolepsy and in OSA. Schedule IV controlled substance.
• Cheyne-Stokes respiration: A cyclical breathing pattern of gradually increasing then decreasing respiratory effort, culminating in a central apnea, before the cycle repeats. Characteristic of central sleep apnea in heart failure with reduced ejection fraction.
• DISE (drug-induced sleep endoscopy): A procedure in which a patient is sedated to mimic sleep while a clinician scopes the upper airway to identify the exact site and pattern of collapse. Used to guide surgical planning and assess candidacy for hypoglossal nerve stimulation (Inspire).
• Hypocretin / orexin: A brain signaling chemical (neuropeptide) that promotes and stabilizes wakefulness; loss of orexin-producing neurons causes narcolepsy type 1. Available entries in M–P also cover this term.
• Two-process model: The framework explaining sleep as the interaction of sleep drive (builds with time awake) and the circadian clock (sets when sleep is timed).

• University of Utah Sleep-Wake Center — 1138 E. Wilmington Ave, Salt Lake City, UT 84106. (801) 581-2016. The primary academic sleep medicine program in Utah, offering comprehensive diagnostic testing (PSG, MSLT, MWT, actigraphy), CBT-I, PAP management, and subspecialty evaluation for narcolepsy, parasomnias, and complex insomnia. Named sleep medicine faculty include: Dr. Chitra Lal, MD, FAASM, FACP, FCCP (Medical Director; board-certified pulmonologist and sleep medicine specialist), Dr. Ryan C. Graham, MD (sleep medicine), Dr. Sonia A. Malik, MD (sleep medicine), and Dr. Kelly Glazer Baron, PhD, MPH, DBSM (clinical psychologist; Behavioral Sleep Medicine and CBT-I specialist). Affiliated with the U of U Clinical Neurosciences Center and Pulmonary Division.
• Intermountain Health Sleep Medicine — TOSH Clinic — 5770 South 250 East, Suite 340, Murray, UT 84107. (801) 314-2400. Part of Intermountain Health with multiple locations across the Wasatch Front (Murray, Riverton, Park City). Accredited sleep labs with board-certified sleep medicine physicians. Named physicians include Dr. Tom V. Cloward, MD and Dr. Robert L. Mazzola, MD. Provides home and in-lab sleep testing, PAP titration, and follow-up care. Also: Intermountain Sleep Disorders Center at Medical Center (5121 S Cottonwood St, Murray; 801-408-1625).

• Stanford Sleep Medicine Center (Redwood City, CA) — One of the oldest and most influential sleep programs in the world; pioneered much of modern sleep medicine including narcolepsy research and the discovery of orexin. Subspecialty expertise in narcolepsy, idiopathic hypersomnia, parasomnias, complex sleep apnea, and circadian disorders. Active clinical trials program.
• Mayo Clinic Center for Sleep Medicine (Rochester, MN; also Scottsdale, AZ and Jacksonville, FL) — Large multidisciplinary program with integrated evaluation across sleep medicine, pulmonology, neurology, psychiatry, and ENT. Particularly strong in complex, multi-disorder cases and second opinions. Comprehensive diagnostic capabilities including advanced PAP titration and hypoglossal nerve stimulation evaluation.
• Cleveland Clinic Sleep Disorders Center (Cleveland, OH) — AASM-accredited center with expertise across the full range of sleep disorders; integrated with one of the largest neurology and pulmonology departments in the country. Strong programs in sleep apnea management, narcolepsy, REM sleep behavior disorder, and sleep-related movement disorders.

• VA Salt Lake City Health Care System — Sleep Medicine — Provides sleep evaluation, diagnostic testing, PAP therapy, and CBT-I for enrolled veterans. The VA system nationally has been a leader in implementing evidence-based insomnia treatment, including widespread deployment of CBT-I through trained providers and the CBT-I Coach app. Veterans with sleep complaints should ask their VA primary care provider about referral to sleep medicine and about access to the VA’s CBT-I program.

Veterans enrolled in VA care can access sleep medicine services at most VA medical centers. The VA also offers telehealth sleep appointments, which can be especially useful for veterans in rural areas.

• Canadian Sleep Society (CSS) — The national professional society for sleep research and clinical sleep medicine in Canada. Maintains standards of practice and supports accreditation of sleep labs across the country. Their website provides a directory of accredited sleep facilities and certified sleep medicine physicians by province. Canadian patients can use this as a starting point for finding qualified sleep care in their region.

• European Sleep Research Society (ESRS) — The leading European scientific society for sleep research and sleep medicine. Publishes the Journal of Sleep Research, maintains European guidelines and position papers, runs an accreditation program for sleep medicine centers across Europe, and certifies sleep medicine specialists through its examination program. Patients in Europe can use the ESRS center accreditation directory to find high-quality sleep facilities in their country.

Other national sleep societies (Australasian Sleep Association, British Sleep Society, Japanese Society of Sleep Research, among others) maintain similar directories for their regions.

DORAs (suvorexant, lemborexant, daridorexant) block the brain’s orexin wake-promotion signal and represent the newest class of approved insomnia medication. Pivotal trials supporting their approval: lemborexant Phase 3 SUNRISE 1 (NCT02783729) and SUNRISE 2 (NCT02952820); daridorexant Phase 3 RESTING-1/RESTING-2 (NCT03545191, NCT03575104). Current trials are investigating:

• Long-term safety and efficacy data — Studies extending to 12+ months to establish whether DORAs maintain their benefit without tolerance, rebound, or cognitive effects seen with older sleep medications.
• Special populations — Trials in older adults (where falls and cognitive effects of traditional hypnotics are a particular concern), patients with comorbid psychiatric conditions, and patients with insomnia co-occurring with sleep apnea (COMISA).
• Comparison with CBT-I — Head-to-head and combination trials comparing DORAs with first-line behavioral treatment to define their optimal role in the treatment sequence.

Why it matters: DORAs have a different mechanism from benzodiazepines and Z-drugs, with early data suggesting a more favorable safety profile. If long-term data holds up, they may fill a genuine gap for patients who need pharmacological support alongside or after CBT-I.

Hypoglossal nerve stimulation (the Inspire system is the best known) activates the nerve that controls the tongue during sleep, preventing airway collapse without a mask. Key trial directions:

• Long-term durability data — Registry studies and the STAR trial (NCT01161420) extension are reporting outcomes at 5+ years, confirming sustained AHI reduction and adherence in carefully selected patients. Ongoing data collection continues to refine the long-term benefit-risk profile.
• Expanded eligibility — Trials are testing whether patients with higher BMI (above the current cutoff of approximately 35 kg/m²), complete concentric collapse patterns (currently excluded), or milder OSA may also benefit.
• Comparative effectiveness — Studies comparing hypoglossal nerve stimulation with optimized CPAP therapy and with oral appliances to help define which patients benefit most from each approach.

Why it matters: For the subset of patients with moderate-to-severe OSA who genuinely cannot tolerate PAP therapy, this is the most established surgical alternative with durable data. Expanding the eligible population could make it an option for more patients.

Digital CBT-I programs that deliver the actual components of cognitive behavioral therapy for insomnia via app or web platform are an active area of development. Current trial directions:

• Prescription digital therapeutics (PDTs) — FDA-cleared programs are being tested in larger, more diverse populations, including patients with significant comorbidities (depression, chronic pain, PTSD) and underserved communities where in-person CBT-I providers are scarce.
• Adaptive and personalized delivery — Trials are testing whether tailoring the CBT-I program to individual sleep patterns and preferences (using sensor data and patient input) improves adherence and outcomes compared with one-size-fits-all protocols.
• Integration with primary care — Studies evaluating digital CBT-I as a standard part of primary care insomnia management, with the goal of making first-line treatment accessible to the majority of insomnia patients who never see a sleep specialist.
• Combination with pharmacotherapy — Trials investigating sequential and combination approaches — for example, starting a DORA for immediate relief while digital CBT-I builds the behavioral foundation for long-term improvement.

Why it matters: Access to trained CBT-I providers remains the single biggest barrier to first-line insomnia treatment. High-quality digital programs that are validated, accessible, and affordable could close this gap for millions of people.

For the first time, medications taken as a nightly pill to treat obstructive sleep apnea are in advanced clinical development. The most advanced is AD109, a fixed-dose combination of aroxybutynin and atomoxetine that works by increasing the tone of the upper airway muscles during sleep. Key trial directions:

• SynAIRgy Phase 3 trial (NCT05813275) — A randomized, placebo-controlled trial that met its primary endpoint, showing a statistically significant reduction in AHI compared to placebo. The developer (Apnimed) submitted a New Drug Application (NDA) to the FDA, with a target review date in 2026.
• LunAIRo companion trial (NCT05811247) — A 51-week Phase 3 trial providing long-term safety and efficacy data for AD109.
• Other combinations — Several other drug combinations targeting airway muscle tone during sleep are in earlier-stage trials.

Why it matters: If approved, AD109 would be the first oral medication specifically designed to treat obstructive sleep apnea, offering a mask-free, non-surgical option for patients who cannot tolerate CPAP. This would represent a major expansion of the OSA treatment toolkit. However, it would not eliminate the need for a sleep study diagnosis or for follow-up testing to confirm treatment response.

Narcolepsy research has entered a landmark phase, with the first orexin-replacement therapy approaching FDA approval and an established once-nightly sodium oxybate option now available.

• Oveporexton (TAK-861) — FirstLight Phase 3 (NCT06470828) — Randomized, placebo-controlled Phase 3 trial in narcolepsy type 1 evaluating oveporexton, an orexin-2 receptor agonist designed to restore the missing wake-promoting signal. Met all primary and key secondary endpoints in 2025 (excessive daytime sleepiness, cataplexy frequency, nocturnal sleep). FDA NDA accepted with Priority Review February 2026; PDUFA target Q3 2026. Not yet approved.
• Oveporexton (TAK-861) — RadiantLight Phase 3 (NCT06505031) — Companion Phase 3 trial providing additional safety and efficacy data across the dose range. Positive results support the NDA submission. Not yet approved.
• REST-ON — Lumryz pivotal trial (NCT02720744) — The Phase 3 trial of once-nightly extended-release sodium oxybate (FT218, now marketed as Lumryz by Avadel) in narcolepsy types 1 and 2. Demonstrated significant improvement in excessive daytime sleepiness, cataplexy frequency, and nocturnal sleep disruption vs. placebo. This trial led directly to FDA approval of Lumryz in May 2023. Lumryz is now the only once-nightly sodium oxybate option, eliminating the middle-of-night re-dose required by Xyrem and Xywav.

Why it matters: Oveporexton would be the first therapy to directly replace the missing orexin signal — a mechanistically different approach from all current narcolepsy treatments. If approved in Q3 2026, it would represent the most significant advance in narcolepsy management in two decades.

• ClinicalTrials.gov — The official U.S. registry of clinical trials. Search by condition (e.g., “insomnia,” “obstructive sleep apnea,” “narcolepsy”), intervention, or location. Filter for recruiting studies near you.
• Ask your sleep specialist. Academic sleep centers (listed above) are the most likely to have active trials. Your clinician can help assess whether a trial is appropriate for your specific situation.
• What to ask before enrolling: What is the specific treatment being tested? What is the control group (placebo, standard care)? What are the time commitments, visits, and procedures? What are the known risks? Will you have access to the treatment after the trial ends? Is there any cost to you?

Clinical trial participation is voluntary. You can withdraw at any time. A trial is not a shortcut to treatment — it is a contribution to research that may or may not benefit you directly. Discuss with your clinician before enrolling.